Document:

<PAGE>

                                                                     EXHIBIT 4.9

                     SERIES H REGISTRATION RIGHTS AGREEMENT

            This Registration Rights Agreement (the "Agreement") is executed as
of the 2nd day of December, 2003 by BioNumerik Pharmaceuticals, Inc., a Texas
corporation (the "Company").

                              W I T N E S S E T H:

            WHEREAS, the persons identified on Schedule A hereto (the
"Purchasers") have agreed to purchase shares of the Company's Preferred Stock
(as defined herein) with the understanding that the Company would grant certain
registration rights to the Purchasers.

            NOW, THEREFORE, the Company grants the registration rights contained
herein to the Purchasers, subject to the terms and conditions contained herein:

            1. CERTAIN DEFINITIONS. As used in this Agreement, the following
terms shall have the following respective meanings:

            "Commission" means the Securities and Exchange Commission or any
other federal agency at the time administering the Securities Act.

            "Common Stock" means the Common Stock, par value $.01 per share, of
the Company.

            "Conversion Shares" means the shares of Common Stock issued and
issuable upon conversion of the Preferred Stock issued to the Purchasers
(including shares of Common Stock issued and issuable upon conversion of the
Preferred Stock issued and issuable pursuant to the exercise of warrants (the
"Warrants") to purchase Preferred Stock issued by the Company in connection with
the sale of the Preferred Stock).

            "Exchange Act" means the Securities Exchange Act of 1934, as
amended, or any similar federal statute and the rules and regulations of the
Commission thereunder, all as the same shall be in effect at the time.

            "Holders" means the Purchasers and any holder of Registrable
Securities to whom the registration rights conferred by this Agreement have been
transferred in compliance with Section 2.10 hereof.

            "Initiating Holders" means any Holder or Holders who in the
aggregate hold more than fifty percent (50%) of the then-outstanding Registrable
Securities, but no less than the number of Registrable Securities issued or
issuable upon conversion of twenty five percent (25%) of the total number of
shares of Preferred Stock issued by the Company to the Purchasers.

            "Preferred Stock" means the Series H Convertible Preferred Stock,
par value $.01 per share, of the Company.
<PAGE>
            "Registrable Securities" means (i) the Conversion Shares and (ii)
any Common Stock issued as a dividend or other distribution with respect to or
in exchange for or in replacement of the Conversion Shares or the Preferred
Stock issued to the Purchasers, provided, however, that Registrable Securities
shall not include any shares of Common Stock which have previously been
registered or which have been sold pursuant to Rule 144.

            The terms "register," "registered" and "registration" refer to a
registration effected by preparing and filing a registration statement in
compliance with the Securities Act, and the declaration or ordering of the
effectiveness of such registration statement.

            "Rule 144" means Rule 144 as promulgated by the Commission under the
Securities Act, as such Rule may be amended from time to time, or any similar
successor rule that may be promulgated by the Commission.

            "Series A Persons" means those persons entitled to registration
rights pursuant to registration rights granted by the Company to holders of its
Series A Convertible Preferred Stock.

            "Series B Persons" means those persons entitled to registration
rights pursuant to registration rights granted by the Company to holders of its
Series B Convertible Preferred Stock.

            "Series C Persons" means those persons entitled to registration
rights pursuant to registration rights granted by the Company to holders of its
Series C Convertible Preferred Stock.

            "Series D Persons" means those persons entitled to registration
rights pursuant to registration rights granted by the Company to holders of its
Series D Convertible Preferred Stock.

            "Series E Persons" means those persons entitled to registration
rights pursuant to registration rights granted by the Company to holders of its
Series E Convertible Preferred Stock.

            "Series F Persons" means those persons entitled to registration
rights pursuant to registration rights granted by the Company to holders of its
Series F Convertible Preferred Stock.

            "Series G Persons" means those persons entitled to registration
rights pursuant to registration rights granted by the Company to holders of its
Series G Convertible Preferred Stock.

            "Securities Act" means the Securities Act of 1933, as amended, or
any similar federal statute and the rules and regulations of the Commission
thereunder, all as the same shall be in effect at the time.

            For purposes of the definitions of "Holder" and "Initiating Holders"
above, holders of Preferred Stock and holders of Warrants shall be deemed to be
the holders of Registrable Securities issuable upon conversion or exercise
thereof; and for the purpose of calculating any percentage of Registrable
Securities, the calculation shall be made as if the Preferred Stock and the
Warrants (and the Preferred Stock issued upon exercise thereof) had been fully
converted or exercised.

                                       2
<PAGE>
            2. REGISTRATION OF REGISTRABLE SECURITIES.

            2.1 Registration on Request.

            (a) Request. Subject to the limitations provided herein, commencing
on December 31, 2005, or on the first anniversary of the effective date of the
Company's first registration statement under the Securities Act, whichever shall
first occur, until the fifth anniversary of the effective date of the Company's
first registration statement under the Securities Act, upon the written request
(specifying that it is being made pursuant to this Section 2.1) of the
Initiating Holders, requesting that the Company effect the registration under
the Securities Act of at least fifty percent (50%) of the then-outstanding
Registrable Securities, but no less than the number of Registrable Securities
issued or issuable upon conversion of twenty five percent (25%) of the total
number of shares of Preferred Stock issued by the Company to the Purchasers, and
specifying (x) the intended method of disposition thereof, (y) whether or not
such requested registration is to be an underwritten offering, and (z) the price
range (net of underwriting discounts and commissions) acceptable to such Holder
or Holders to be received for such Registrable Securities, the Company will
within 10 business days after the Company receives such written request give
written notice of such requested registration to all other Holders of
Registrable Securities and thereupon the Company will use reasonable efforts to
effect the registration under the Securities Act of:

            (i) the Registrable Securities which the Company has been so
      requested to register by such Initiating Holders, and

            (ii) all other Registrable Securities which the Company has been
      requested to register by the other Holders thereof by written request
      given to the Company within 15 days after the giving of such written
      notice by the Company (which request shall specify the same information
      called for by the original request to effect registration described
      above), all to the extent requisite to permit the disposition (in
      accordance with Section 2.1(b) hereof) of the Registrable Securities so to
      be registered.

            (b) Method of Distribution. The Holders of 51% of the Registrable
Securities to be included in such registration statement shall determine the
method of distribution of the Registrable Securities so included; provided,
however, that if no agreement of Holders of 51% or more of the Registrable
Securities to be included in such registration statement is obtained, then if
Holders of more than 30% of the Registrable Securities to be included in such
registration statement request an underwritten public offering, an underwritten
public offering shall be the method of distribution with other methods permitted
to the extent the managing underwriter for such offering, in its sole
discretion, agrees to other methods of distribution being covered by such
registration statement.

            (c) Registration of Other Securities. Whenever the Company shall
effect a registration pursuant to this Section 2.1 in connection with an
underwritten offering, no securities other than Registrable Securities shall be
included among the securities covered by such registration unless (i) the
managing underwriter of such offering shall have advised each Holder of
Registrable Securities to be covered by such registration in writing that the
inclusion of such other securities would not adversely affect such offering or
(ii) the Holders of more than 51% or more of all

                                       3
<PAGE>
Registrable Securities to be covered by such registration shall have consented
in writing to the inclusion of such other securities; provided, however, that
the rights of Holders hereunder shall be subject to (A) the prior right of
Series A Persons requesting registration (whether pursuant to "demand" or
"piggyback" registration rights) to include all of the securities requested to
be registered by such Series A Persons in such registration, and (B) the
concurrent right of Series B Persons, Series C Persons, Series D Persons, Series
E Persons, Series F Persons, Series G Persons and persons holding securities
obtained through the exercise of warrants issued to certain placement agents and
finders in connection with the sale of the Company's Series E Convertible
Preferred Stock (the "Series E Warrant Purchasers") requesting registration
pursuant to the registration rights granted by the Company to such Series B
Persons, Series C Persons, Series D Persons, Series E Persons, Series F Persons,
Series G Persons, and Series E Warrant Purchasers (whether pursuant to "demand"
or "piggyback" registration rights) to include securities in such registration
on a pro rata basis with the Registrable Securities of Holders to be included in
such registration, so that the relative proportion of the amount of securities
held by Series B Persons, Series C Persons, Series D Persons, Series E Persons,
Series F Persons, Series G Persons, Series E Warrant Purchasers and Holders that
are actually included in such registration is the same as the relative
proportion of the total amount of securities held by Series B Persons, Series C
Persons, Series D Persons, Series E Persons, Series F Persons, Series G Persons,
Series E Warrant Purchasers and Holders that are requested to be included in
such registration pursuant to the registration rights granted by the Company to
such Series B Persons, Series C Persons, Series D Persons, Series E Persons,
Series F Persons, Series G Persons, Series E Warrant Purchasers or Holders, as
the case may be.

            (d) Registration Statement Form. Registrations under this Section
2.1 shall be on such appropriate registration form of the Commission (i) as
shall be selected by the Company, and (ii) as shall permit the disposition of
such Registrable Securities in accordance with the method or methods of
disposition selected pursuant to Section 2.1(b) hereof.

            (e) Expenses. Except as otherwise provided in this Section 2.1(e) or
in Section 2.1(i), the Company shall bear all expenses incurred in connection
with two effective registrations pursuant to Section 2.1 hereof and each
registration pursuant to Section 2.2 hereof (excluding in each case underwriting
discounts and commissions applicable to Registrable Securities), including,
without limitation, in each case: (i) all registration, filing and National
Association of Securities Dealers fees; (ii) all fees and expenses of complying
with securities or blue sky laws; (iii) all word processing, duplicating and
printing expenses, messenger, delivery and shipping expenses; (iv) the fees and
disbursements of the accountants and counsel for the Company including the
expenses of any special audits or "cold comfort" letters or opinions required by
or incident to such registrations; (v) the fees and disbursements of the
accountants and counsel for the Company for services rendered in connection with
inclusion of Registrable Securities in the registration; provided, however, that
if the accountants or the counsel for the Company refuse or decline to undertake
such representation because of an actual or perceived conflict of interest or
otherwise, then the Company shall bear the reasonable fees and disbursements of
one firm of counsel and one firm of accountants (as appropriate) retained by the
Holders of such Registrable Securities; (vi) premiums and other costs of
policies of insurance maintained for the benefit of the Company against
liabilities arising out of the public offering of the Registrable Securities;
(vii) any fees and disbursements of underwriters customarily paid by issuers or
sellers of securities, but excluding underwriting discounts and commissions, if
any. In all cases, each Holder of Registrable Securities shall pay the
underwriting discounts and commissions applicable to the securities sold by such
Holder.

                                       4
<PAGE>
            (f) Effective Registration Statement. The Company's obligation to
effect a registration requested pursuant to this Section 2.1 shall not be deemed
to have been fulfilled (i) unless a registration statement with respect thereto
has become effective (unless a substantial cause of the failure of such
registration statement to become effective shall be attributable to one or more
Holders of Registrable Securities whose securities were to have been included in
such registration statement), (ii) if after it has become effective, such
registration is interfered with by any stop order, injunction or other order or
requirement of the Commission or other governmental agency or court for any
reason, resulting in a failure to consummate the offering of Registrable
Securities offered thereby, (iii) if after a registration statement with respect
thereto has become effective, the offering of Registrable Securities offered
thereby is not consummated due to factors beyond the control of the Holders of
such Registrable Securities, including without limitation in the context of a
proposed firm commitment underwriting, the fact that the underwriters have
advised the Holders of such Registrable Securities that such Registrable
Securities cannot be sold at a net price equal to or above the net price
specified in the notice to the Company at the time of the request, or (iv) if
the conditions to closing specified in the purchase agreement or underwriting
agreement entered into in connection with such registration are not satisfied
(unless a substantial cause of such conditions to closing not being satisfied
shall be attributable to one or more Holders of Registrable Securities whose
Registrable Securities were included in such registration statement).

            (g) Selection of Underwriters. If a requested registration pursuant
to this Section 2.1 involves an underwritten offering, the underwriter or
underwriters thereof shall be selected by the Company with the approval of the
Holders of at least 50% of the Registrable Securities to be so registered, which
approval will not be unreasonably withheld.

            (h) Priority in Requested Registrations. If a requested registration
pursuant to this Section 2.1 involves an underwritten offering, and the managing
underwriter shall advise the Company in writing (with a copy to each Holder
requesting registration) that, in its opinion, the number of securities
requested to be included in such registration exceeds the number which can be
sold in such offering within a price range acceptable to the Holders of more
than 50% of the Registrable Securities requested to be included in such
registration, then the Registrable Securities requested to be registered
pursuant to this Section 2.1 shall be reduced to the number of Registrable
Securities which the Company is so advised can be sold in (or during the time
of) such offering by decreasing the Registrable Securities requested to be
registered (pro rata among the Holders requesting such registration on the basis
of the percentage of the Registrable Securities held by such Holder immediately
prior to the filing of the registration statement with respect to such
registration). Nothing in this Section 2.1(h) shall affect (i) the rights of
Series A Persons requesting registration to include all of the securities
requested to be registered by such Series A Persons in such registration without
reduction prior to the inclusion of any Registrable Securities requested to be
registered hereunder, or (ii) the rights of Series B Persons, Series C Persons,
Series D Persons, Series E Persons, Series F Persons, Series G Persons, and
Series E Warrant Purchasers requesting registration to include securities in
such registration on a pro rata basis with the Registrable Securities of Holders
hereunder in the same manner as described in Section 2.1(c) hereof.

            (i) Form S-3. Notwithstanding the other provisions of this Section
2.1, until the fifth anniversary of the effective date of the Company's first
registration statement under the Securities Act, the Company shall be required
upon the written request of Holder(s) by this Section 2.1 to effect, and

                                       5
<PAGE>
bear all expenses (as determined pursuant to Section 2.1(e) hereof) incurred in
connection with, up to two registrations on Form S-3 (or any successor similar
form) of Registrable Securities during such period, provided that the
Registrable Securities to be registered thereon are expected to have an
aggregate disposition price (before deductions for underwriting discounts and
commissions) of at least $500,000.

            (j) Until the fifth anniversary of the effective date of the
Company's first registration statement under the Securities Act, the Company
shall be required, upon the written request of Holder(s) in accordance with this
Section 2.1 and subject to the other provisions contained in this Section 2.1,
to effect, and bear all expenses (as determined pursuant to Section 2.1(e)
hereof) incurred in connection with, up to two registrations pursuant to this
Section 2.1 (other than registrations on Form S-3 or any successor similar
form). Notwithstanding anything to the contrary contained herein, no Holder
shall have the right to request registration of Registrable Securities pursuant
to this Section 2.1 or to include Registrable Securities in an incidental
registration pursuant to Section 2.2 with respect to any Registrable Securities
that such Holder is eligible to sell under Rule 144 of the Securities Act within
any three month period or under Rule 144(k) of the Securities Act without any
volume limitations. In addition, the Company shall not be obligated to prepare
and file any other registration statement pursuant to this Section 2.1 within
180 days of the consummation of an underwritten public offering of Common Stock
pursuant to a registration statement filed under the Securities Act.

            2.2 Incidental Registration.

            (a) Right to Include Registrable Securities. If the Company at any
time prior to the fifth anniversary of the effective date of the Company's first
registration statement under the Securities Act proposes to register any of its
securities under the Securities Act (other than by a registration on Form S-8,
S-4 or any successor similar forms or any other form not available for
registering the Registrable Securities for sale to the public and other than
pursuant to Section 2.1 hereof), whether or not for sale for its own account, it
will each such time, at least 15 days prior to filing the registration
statement, give written notice to all Holders of Registrable Securities of its
intention to do so. Upon the written request of Holders of an aggregate of at
least 25,000 shares (appropriately adjusted for subdivisions and combinations of
shares of Common Stock and dividends on Common Stock payable in shares of Common
Stock hereafter) of Registrable Securities, made within 15 days after the
receipt of any such notice (which request shall specify the Registrable
Securities intended to be disposed of by each such Holder and the intended
method of disposition thereof), the Company will use reasonable efforts to
effect the registration under the Securities Act of all Registrable Securities
which the Company has been so requested to register by the Holders of such
Registrable Securities, to the extent requisite to permit the disposition
(determined pursuant to the provisions of Section 2.1(b) hereof) of the
Registrable Securities so to be registered, provided that if, at any time after
giving written notice of its intention to register any securities and prior to
the effective date of the registration statement filed in connection with such
registration, the Company shall determine for any reason not to register or to
delay registration of such securities, the Company may, at its election, give
written notice of such determination to each Holder of Registrable Securities
and, thereupon, (i) in the case of a determination not to register, shall be
relieved of its obligation to register any Registrable Securities in connection
with such registration (but not from its obligation to pay expenses in
accordance with Section 2.1(e) hereof), without prejudice, however, to the
rights of any Holder or Holders of

                                       6
<PAGE>
Registrable Securities entitled to do so to request that such registration be
effected as a registration under Section 2.1 hereof, and (ii) in the case of a
determination to delay registering, shall be permitted to delay registering any
Registrable Securities being registered pursuant to this Section 2.2(a), for the
same period as the delay in registering such other securities. No registration
effected under this Section 2.2 shall relieve the Company of its obligation to
effect any registration upon request under Section 2.1 hereof.

            (b) Priority in Incidental Registrations. If (i) a registration
pursuant to this Section 2.2 involves an underwritten offering of the securities
so being registered, whether or not for sale for the account of the Company, to
be distributed (on a firm commitment basis) by or through one or more
underwriters of recognized standing, whether or not the Registrable Securities
so requested to be registered for sale for the account of Holders of Registrable
Securities are also to be included in such underwritten offering, and (ii) the
managing underwriter of such underwritten offering shall inform the Company and
the Holders of the Registrable Securities requesting such registration by letter
of its belief that the number of securities requested to be included in such
registration exceeds the number which can be sold in (or during the time of)
such offering, then the Company may include in such offering all securities
proposed by the Company to be sold for its own account and may decrease the
number of Registrable Securities and other securities of the Company that
persons have requested to be included in such registration by (a) first
decreasing the securities requested to be included in such registration other
than Registrable Securities (pro rata among the persons requesting such
registration on the basis of the number of shares of such securities held by
such person immediately prior to the filing of the registration statement with
respect to such registration) and (b) then, to the extent necessary, decreasing
the Registrable Securities requested to be registered (pro rata among the
Holders requesting such registration on the basis of the percentage of the
Registrable Securities held by such Holders immediately prior to the filing of
the registration statement with respect to such registration); provided,
however, that the rights of Holders hereunder shall be subject to (i) the right
of the Series A Persons requesting inclusion of securities in such registration
to include all of the securities requested to be registered by such Series A
Persons in such registration without reduction prior to the inclusion of any
Registrable Securities requested to be included in such registration pursuant to
this Section 2.2., and (ii) the rights of Series B Persons, Series C Persons,
Series D Persons, Series E Persons, Series F Persons, Series G Persons, and
Series E Warrant Purchasers requesting registration to include securities in
such registration on a pro rata basis with the Registrable Securities of Holders
hereunder in the same manner as described in Section 2.1(c) hereof.

            2.3 Registration Procedures. If and whenever the Company is required
to use reasonable efforts to effect the registration of any Registrable
Securities under the Securities Act as provided in Sections 2.1 and 2.2 hereof,
the Company will, subject to the limitations provided herein, as expeditiously
as possible:

            (a) prepare and (as soon thereafter as possible or in any event no
      later than 60 days after the end of the period within which requests for
      registration may be given to the Company or such longer period as the
      Company shall in good faith require to produce the financial statements
      required in connection with such registration) file with the Commission
      the requisite registration statement to effect such registration and
      thereafter use reasonable efforts to cause such registration statement to
      become effective, provided that the Company may discontinue any
      registration of its securities which are not Registrable Securities (and,
      under the

                                       7
<PAGE>
      circumstances specified in Section 2.2(a) hereof, its securities which are
      Registrable Securities) at any time prior to the effective date of the
      registration statement relating thereto;

            (b) prepare and file with the Commission such amendments and
      supplements to such registration statement and the prospectus used in
      connection therewith as may be necessary to keep such registration
      statement effective and to comply with the provisions of the Securities
      Act with respect to the disposition of all securities covered by such
      registration statement until such time as all of such securities have been
      disposed of in accordance with the intended methods of disposition by the
      seller or sellers thereof set forth in such registration statement;
      provided, however, that the Company shall not in any event be required to
      keep the registration statement effective for a period of more than three
      months after such registration statement becomes effective;

            (c) furnish to each seller of Registrable Securities covered by such
      registration statement such number of conformed copies of such
      registration statement and of each such amendment and supplement thereto
      (in each case including all exhibits), such number of copies of the
      prospectus contained in such registration statement (including each
      preliminary prospectus and any summary prospectus) and any other
      prospectus filed under Rule 424 under the Securities Act, and such other
      documents, as such seller may reasonably request;

            (d) use reasonable efforts to register or qualify all Registrable
      Securities and other securities covered by such registration statement
      under such other securities or blue sky laws of such jurisdictions as each
      seller thereof shall reasonably request, to keep such registration or
      qualification in effect for so long as such registration statement remains
      in effect (provided, however, that the Company shall not in any event be
      required to keep such registration or qualification in effect for a period
      of more than three months after such registration or qualification becomes
      effective), and take any other action which may be reasonably necessary or
      advisable to enable such seller to consummate the disposition in such
      jurisdictions of the securities owned by such seller, except that the
      Company shall not for any such purpose be required to qualify generally to
      do business as a foreign corporation in any jurisdiction wherein it would
      not but for the requirements of this subdivision (d) be obligated to be so
      qualified or to consent to general service of process in any such
      jurisdiction;

            (e) use reasonable efforts to cause all Registrable Securities
      covered by such registration statement to be registered with or approved
      by such other United States federal or state governmental agencies or
      authorities as may be necessary to enable the seller or sellers thereof to
      consummate the disposition of such Registrable Securities;

            (f) furnish to each seller of Registrable Securities a copy, or,
      upon request, a signed counterpart, addressed to such seller (and the
      underwriters, if any) of

                  (i) an opinion of counsel for the Company, dated the effective
            date of such registration statement (or, if such registration
            includes an underwritten public offering, dated the date of the
            closing under the underwriting agreement), and

                  (ii) a "comfort" letter addressed to the underwriters, dated
            the effective date of such registration statement (or, if such
            registration includes an underwritten public

                                       8
<PAGE>
            offering, dated the date of the closing under the underwriting
            agreement), signed by the independent public accountants who have
            audited the Company's financial statements included in such
            registration statement, covering substantially the same matters with
            respect to such registration statement (and the prospectus included
            therein) and, in the case of the accountants' letter, with respect
            to events subsequent to the date of such financial statements, as
            are customarily covered in opinions of issuer's counsel and in
            accountants' letters delivered to the underwriters in underwritten
            public offerings of securities and, in the case of the accountants'
            letter, such other financial matters, and, in the case of the legal
            opinion such other legal matters, as such seller or such Holder (or
            the underwriters, if any) may reasonably request;

            (g) notify each seller of Registrable Securities covered by such
      registration statement, at any time when a prospectus relating thereto is
      required to be delivered under the Securities Act, upon discovery that, or
      upon the happening of any event as a result of which, the prospectus
      included in such registration statement, as then in effect, includes an
      untrue statement of a material fact or omits to state any material fact
      required to be stated therein or necessary to make the statements therein
      not misleading in the light of the circumstances under which they were
      made, and at the request of any such seller, prepare and furnish to such
      seller a reasonable number of copies of a supplement to or an amendment of
      such prospectus as may be necessary so that, as thereafter delivered to
      the purchasers of such securities, such prospectus shall not include an
      untrue statement of a material fact or omit to state a material fact
      required to be stated therein or necessary to make the statements therein
      not misleading in the light of the circumstances under which they were
      made;

            (h) otherwise use reasonable efforts to comply with all applicable
      rules and regulations of the Commission, and make available to its
      security holders, as soon as reasonably practicable, an earnings statement
      covering the period of at least twelve months beginning with the first
      full calendar month after the effective date of such registration
      statement, which earnings statement shall satisfy the provisions of
      Section 11(a) of the Securities Act, and will furnish to each such seller,
      upon request of such seller, prior to the filing thereof a copy of any
      amendment or supplement to such registration statement or prospectus and
      shall not file any such supplement or amendment if such seller shall have
      delivered to the Company an opinion of counsel that such amendment or
      supplement does not comply in all material respects with the requirements
      of the Securities Act or of the rules or regulations thereunder;

            (i) provide and cause to be maintained a transfer agent for all
      Registrable Securities covered by such registration statement from and
      after a date not later than the effective date of such registration
      statement;

            (j) use reasonable efforts to list all Registrable Securities
      covered by such registration statement on any securities exchange on which
      the Common Stock is then listed; and

            (k) refrain from making any sale or distribution of its equity
      securities, except pursuant to any employee stock option or stock purchase
      plan or other employee benefit plan and any preexisting agreement for the
      sale of such securities, for at least 90 days after the closing of the
      public offering pursuant to such registration.

                                       9
<PAGE>
            It shall be a condition precedent to the obligations of the Company
to take any action with respect to registering a Holder's Registrable Securities
pursuant to this Section 2.3 that such seller of Registrable Securities as to
which any registration is being effected furnish the Company in writing such
information regarding such seller, the Registrable Securities and other
securities of the Company held by such seller, and the distribution of such
securities as the Company may from time to time reasonably request in writing.
If a Holder refuses to provide the Company with any of such information on the
grounds that it is not necessary to include such information in the registration
statement, the Company may exclude such Holder's Registrable Securities from the
registration statement if the Company provides such Holder with an opinion of
counsel to the effect that such information must be included in the registration
statement and such Holder thereafter continues to withhold such information. The
deletion of such Holder's Registrable Securities from a registration statement
shall not affect the registration of the other Registrable Securities to be
included in such registration statement.

            Each Holder of Registrable Securities agrees by acquisition of such
Registrable Securities that upon receipt of any notice from the Company of the
happening of any event of the kind described in Section 2.3(g), such Holder will
forthwith discontinue such Holder's disposition of Registrable Securities
pursuant to the registration statement relating to such Registrable Securities
until such Holder's receipt of the copies of the supplemented or amended
prospectus contemplated by Section 2.3(g) and, if so directed by the Company,
will deliver to the Company (at the Company's expense) all copies, other than
permanent file copies then in such Holder's possession, of the prospectus
relating to such Registrable Securities current at the time of receipt of such
notice.

            2.4 Underwritten Offerings.

            (a) Requested Underwritten Offerings. If requested by the
underwriters for any underwritten offering of Registrable Securities pursuant to
a registration requested under Section 2.1 hereof, the Company will enter into
an underwriting agreement with such underwriters for such offering, the portions
of such agreement that relate to Holders of Registrable Securities being
registered to be reasonably satisfactory in substance and form to each Holder of
Registrable Securities being registered and to contain such representations and
warranties by the Company and such other terms as are generally prevailing in
agreements of this type, including, without limitation, indemnities
substantially to the effect and to the extent provided in Section 2.6 hereof.
Each such Holder of Registrable Securities will cooperate with the Company in
the negotiation of the underwriting agreement and will give consideration to the
reasonable requests of the Company regarding the form thereof, provided that
nothing herein contained shall diminish the foregoing obligations of the
Company. If requested by the underwriters of any underwritten offering pursuant
to a registration under Section 2.1 hereof, each Holder of Registrable
Securities agrees to enter into an agreement with such underwriters not to sell
his or its shares of stock in the Company for a period of time (not to exceed
180 days) after the effectiveness of a registration statement equal to the
period of time which the sellers of securities in such registration, by separate
agreement with the underwriters, have agreed not to sell their shares after the
effectiveness of such registration statement. The Holders of Registrable
Securities to be distributed by such underwriters shall be parties to such
underwriting agreement. Any such Holder shall not be required to make any
representations or warranties to or agreements with the Company or the
underwriters other than representations, warranties or agreements regarding such
Holder, such Holder's Registrable Securities and other securities of the
Company, such

                                       10
<PAGE>
Holder's intended method of distribution, and any representations, warranties or
agreements required by law.

            (b) Incidental Underwritten Offerings. If the Company at any time
proposes to register any of its securities under the Securities Act as
contemplated by Section 2.2 hereof and such securities are to be distributed by
or through one or more underwriters, the Company will, if requested by any
Holder of Registrable Securities as provided in Section 2.2 hereof and subject
to the provisions of Section 2.2(b) hereof, arrange for such underwriters to
include all the Registrable Securities to be offered and sold by such Holder
owning the securities to be distributed by such underwriters. In such event, the
Holders of Registrable Securities to be distributed by such underwriters shall
be parties to the underwriting agreement between the Company and such
underwriters. Any such Holder shall not be required to make any representations
or warranties to or agreements with the Company or the underwriters other than
representations, warranties or agreements regarding such Holder, such Holder's
Registrable Securities or other securities of the Company, such Holder's
intended method of distribution and any representations, warranties or
agreements required by law.

            2.5 Preparation; Reasonable Investigation. In connection with the
preparation and filing of each registration statement under the Securities Act
pursuant to this Agreement, the Company will give the Holders of Registrable
Securities registered under such registration statement, their underwriters, if
any, and one counsel or firm of counsel and one accountant or firm of
accountants representing all the Holders of Registrable Securities to be
registered under such registration statement, the opportunity to participate in
the preparation of such registration statement, each prospectus included therein
or filed with the Commission, and each amendment thereof or supplement thereto,
and will give each of them such access to its books and records and such
opportunities to discuss the business of the Company with its officers and the
independent public accountants who have certified its financial statements as
shall be necessary, in the opinion of such Holders' and such underwriters'
respective counsel, to conduct a reasonable investigation within the meaning of
the Securities Act.

            2.6 Indemnification.

            (a) Indemnification by the Company. In the event any Registrable
Securities are included in a registration statement under this Section 2, to the
extent permitted by law, the Company will, and hereby does, indemnify and hold
harmless the seller of any Registrable Securities covered by such registration
statement, its directors and officers, each other person who participates as an
underwriter in the offering or sale of such securities and each other person, if
any, who controls such seller or any such underwriter within the meaning of the
Securities Act, against any losses, claims, damages or liabilities, joint or
several, to which such seller or any such director or officer or underwriter or
controlling person may become subject under the Securities Act or otherwise,
insofar as such losses, claims, damages or liabilities (or actions or
proceedings, whether commenced or threatened, in respect thereof) arise out of
or are based upon any untrue statement or alleged untrue statement of any
material fact contained in any registration statement under which such
securities were registered under the Securities Act, any preliminary prospectus,
final prospectus or summary prospectus contained therein, or any amendment or
supplement thereto, or any omission or alleged omission to state therein a
material fact required to be stated therein or necessary to make the statements
therein not misleading, and the Company will reimburse such seller and each such
director, officer, underwriter and controlling person for any legal or any other
expenses reasonably incurred by

                                       11
<PAGE>
them in connection with investigating or defending any such loss, claim,
liability, action or proceeding; provided that the Company shall not be liable
in any such case to the extent that any such loss, claim, damage, liability (or
action or proceeding in respect thereof) or expense arises out of or is based
upon an untrue statement or alleged untrue statement or omission or alleged
omission made in such registration statement, any such preliminary prospectus,
final prospectus, summary prospectus, amendment or supplement in reliance upon
and in conformity with written information furnished to the Company by such
seller expressly for use in the preparation thereof, and provided further that
the Company shall not be liable to any person who participates as an underwriter
in the offering or sale of Registrable Securities or any other Person, if any,
who controls such underwriter within the meaning of the Securities Act, in any
such case to the extent that any such loss, claim, damage, liability (or action
or proceeding in respect thereof) or expense arises out of such person's failure
to send or give a copy of the final prospectus, as the same may be then
supplemented or amended, to the person asserting an untrue statement or alleged
untrue statement or omission or alleged omission at or prior to the written
confirmation of the sale of the Registrable Securities to such person if such
statement or omission was corrected in such final prospectus. Such indemnity
shall remain in full force and effect regardless of any investigation made by or
on behalf of such seller or any such director, officer, underwriter or
controlling person and shall survive the transfer of such securities by such
seller.

            (b) Indemnification by the Sellers. The Company may require, as a
condition to including any Registrable Securities in any registration statement
filed pursuant to Section 2.3 hereof, that the Company shall have received an
undertaking satisfactory to it from the prospective seller of such securities,
to indemnify and hold harmless (in the same manner and to the same extent as set
forth in subdivision (a) of this Section 2.6) each underwriter, each person who
controls such underwriter within the meaning of the Securities Act, the Company,
each director of the Company, each officer of the Company and each other person,
if any, who controls the Company within the meaning of the Securities Act, with
respect to any statement or alleged statement in or omission or alleged omission
from such registration statement, any preliminary prospectus, final prospectus
or summary prospectus contained therein, or any amendment or supplement thereto,
if such statement or alleged statement or omission or alleged omission was made
in reliance upon and in strict conformity with written information furnished to
the Company by such seller expressly for use in the preparation of such
registration statement, preliminary prospectus, final prospectus, summary
prospectus, amendment or supplement; provided that such prospective seller shall
not be liable to any person who participates as an underwriter in the offering
or sale of Registrable Securities or any other person, if any, who controls such
underwriter within the meaning of the Securities Act, in any such case to the
extent that any such loss, claim, damage, liability (or action or proceeding in
respect thereof) or expense arises out of such person's failure to send or give
a copy of the final prospectus, as the same may be then supplemented or amended,
to the person asserting an untrue statement or alleged untrue statement or
omission or alleged omission at or prior to the written confirmation of the sale
of Registrable Securities to such person if such statement or omission was
corrected in such final prospectus. Such indemnity shall remain in full force
and effect, regardless of any investigation made by or on behalf of any
underwriter, the Company or any such director, officer or controlling person and
shall survive the transfer of such securities by such seller. In no event shall
the liability of any selling holder of Registrable Securities under this Section
2.6(b) be greater in amount than the dollar amount of the proceeds received by
such holder upon the sale of the Registrable Securities giving rise to such
indemnification obligation.

                                       12
<PAGE>
            (c) Notices of Claims, etc. Promptly after receipt by an indemnified
party of notice of the commencement of any action or proceeding involving a
claim referred to in the preceding subdivisions of this Section 2.6, as a
condition to the obligations of the indemnifying party with respect thereto,
such indemnified party will, if a claim in respect thereof is to be made against
an indemnifying party, give written notice to the latter of the commencement of
such action; provided that the failure of any indemnified party to give notice
as provided herein shall not relieve the indemnifying party of its obligations
under the preceding subdivisions of this Section 2.6, except to the extent that
the indemnifying party is actually prejudiced by such failure to give notice. In
case any such action is brought against an indemnified party, the indemnifying
party shall be entitled to participate in and to assume the defense thereof,
jointly with any other indemnifying party similarly notified to the extent that
it may wish, with counsel reasonably satisfactory to such indemnified party, and
after notice from the indemnifying party to such indemnified party of its
election so to assume the defense thereof, the indemnifying party shall not be
liable to such indemnified party for any legal or other expenses subsequently
incurred by the latter in connection with the defense thereof other than
reasonable costs of investigation. No indemnifying party shall, without the
consent of the indemnified party, consent to entry of any judgment or enter into
any settlement which does not include as an unconditional term thereof the
giving by the claimant or plaintiff to such indemnified party of a release from
all liability in respect to such claim or litigation.

            (d) Other Indemnification. Indemnification similar to that specified
in the preceding subdivisions of this Section 2.6 (with appropriate
modifications) shall be given by the Company and each seller of Registrable
Securities with respect to any required registration or other qualification of
securities under any federal or state law or regulation of any governmental
authority other than the Securities Act.

            (e) Indemnification Payments. The indemnification required by this
Section 2.6 shall be made by periodic payments of the amount thereof during the
course of the investigation or defense, as and when bills are received or
expense, loss, damage or liability is incurred.

            (f) Contribution. If the indemnification provided for in this
Section 2.6 from the indemnifying party is unavailable to an indemnified party
hereunder in respect of any losses, claims, damages, liabilities or expenses
referred to therein, then the indemnifying party, in lieu of indemnifying such
indemnified party, shall contribute to the amount paid or payable by such
indemnified party as a result of such loss, claims, damages, liabilities or
expenses in such proportion as is appropriate to reflect the relative fault of
the indemnifying party and indemnified parties in connection with the actions
which resulted in such losses, claims, damages, liabilities or expenses, as well
as any other relevant equitable considerations. The relative fault of such
indemnifying party and indemnified parties shall be determined by reference to,
among other things, whether any action in question, including any untrue
statement of material fact or omission or alleged omission to state a material
fact, has been made by, or relates to information supplied by, such indemnifying
party or indemnified parties, and the parties' relative intent, knowledge,
access to information and opportunity to correct or prevent such action. The
amount paid or payable by a party as a result of the losses, claims, damages,
liabilities and expenses referred to above shall be deemed to include, subject
to the limitations set forth in Section 2.6(c) hereof, any legal or other fees
or expenses reasonably incurred by such party in connection with any
investigation or proceeding.

                                       13
<PAGE>
            The Company and, as a condition to the registration of any of their
Registrable Securities, the Holders agree that it would not be just and
equitable if contribution pursuant to this Section 2.6(f) were determined by pro
rata allocation or by any other method of allocation which does not take account
of the equitable considerations referred to in the immediately preceding
paragraph. Notwithstanding the provisions of this Section 2.6(f), no underwriter
shall be required to contribute any amount in excess of the amount by which the
aggregate total price at which the Registrable Securities underwritten by it and
distributed to the public were offered to the public exceeds the amount of any
damages which such underwriter has otherwise been required to pay by reason of
such untrue or alleged untrue statement or omission or alleged omission, and no
selling Holder shall be required to contribute any amount in excess of the
amount by which the aggregate total price at which the Registrable Securities of
such selling Holder were offered to the public exceeds the amount of any damages
which such selling Holder has otherwise been required to pay by reason of such
untrue or alleged untrue statement or omission. No person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act)
shall be entitled to contribution from any person who was not guilty of such
fraudulent misrepresentation.

            2.7 Reporting Requirements Under Exchange Act. When it is first
legally required to do so, the Company shall register its Common Stock under
Section 12 of the Exchange Act (as hereinafter defined) and shall keep effective
such registration and shall timely file such information, documents and reports
as the Commission may require or prescribe under Section 13 of the Exchange Act.
From and after the effective date of the first registration statement filed by
the Company under the Securities Act, the Company shall (whether or not it shall
then be required to do so) timely file such information, documents and reports
which a corporation, partnership or other entity subject to Section 13 or 15(d)
(whichever is applicable) of the Exchange Act is required to file.

            Immediately upon becoming subject to the reporting requirements of
either Section 13 or 15(d) of the Exchange Act, the Company shall forthwith upon
request furnish any Holder of Registrable Securities (i) a written statement by
the Company that it has complied with such reporting requirements, (ii) a copy
of the most recent annual or quarterly report of the Company, and (iii) such
other reports and documents filed by the Company with the Commission as such
Holder may reasonably request in availing itself of an exemption for the sale of
Registrable Securities without registration under the Securities Act. The
Company acknowledges and agrees that the purposes of the requirements contained
in this Section 2.7 are (a) to enable any such Holder to comply with the current
public information requirement contained in Paragraph (c) of Rule 144 should
such Holder ever wish to dispose of any of the securities of the Company
acquired by it without registration under the Securities Act in reliance upon
Rule 144 (or any other similar exemptive provision) and (b) to qualify the
Company for the use of registration statements on Form S-3. In addition, the
Company shall take such other measures and file such other information,
documents and reports, as shall hereafter be required by the Commission as a
condition to the availability of Rule 144 under the Securities Act (or any
similar exemptive provision hereafter in effect) and the use of Form S-3. The
Company also covenants to use reasonable efforts, to the extent that it is
reasonably within its power to do so, to qualify for the use of Form S-3.

            2.8 Stockholder Information. The Company may require each Holder of
Registrable Securities as to which any registration is to be effected pursuant
to this Section 2 to furnish the Company such information in writing with
respect to such Holder and the distribution of such

                                       14
<PAGE>
Registrable Securities as the Company may from time to time reasonably request
in writing and as shall be required by law or by the Commission in connection
therewith.

            2.9 Forms. All references in this Agreement to particular forms of
registration statements are intended to include, and shall be deemed to include,
references to all successor forms which are intended to replace, or to apply to
similar transactions as, the forms herein referenced.

            2.10 Transfer of Registration Rights. The registration rights
granted to the Holders of Registrable Securities under this Section 2 may not be
transferred without the prior written consent of the Company; provided that such
registration rights may be transferred, in whole or in part, without such prior
written consent in connection with the transfer of Registrable Securities to (i)
an affiliate (defined as any person that directly or indirectly controls, is
controlled by, or is under common control with such Purchaser) of one or more of
the Purchasers or (ii) to an immediate or remote transferee of a Purchaser who
after such transfer is the Holder of at least 50% of the number of Registrable
Securities purchased by such original Purchaser hereunder as set forth on
Schedule A hereto (appropriately adjusted for subdivisions and combinations of
shares of Common Stock and dividends on Common Stock payable in shares of Common
Stock subsequent to the date of this Agreement).

            3. MISCELLANEOUS.

            3.1 GOVERNING LAW. THIS AGREEMENT SHALL BE GOVERNED IN ALL RESPECTS
BY THE LAWS OF THE STATE OF TEXAS WITHOUT REGARD TO THE CONFLICT OF LAWS
PRINCIPLES THEREOF.

            3.2 Successors and Assigns. Except as otherwise provided herein, the
provisions hereof shall inure to the benefit of, and be binding upon, the
successors and assigns of the parties hereto.

            3.3. Amendment. Except as expressly provided herein, this Agreement,
or any provision hereof, may be amended, waived, discharged or terminated upon
the written consent of the Company and the Holders holding at least fifty
percent (50%) of the then outstanding Registrable Securities. Notwithstanding
the foregoing, Schedule A to this Agreement may be amended by the Company, in
its sole discretion and without the consent of any Purchasers or Holders, in
order to add additional Purchasers of Series H Convertible Preferred Stock of
the Company to Schedule A and to this Agreement, and, upon such amendment by the
Company, such additional purchasers of Series H Convertible Preferred Stock
shall become "Purchasers" for all purposes under this Agreement.

            3.4 Notices, etc. All notices and other communications required or
permitted hereunder shall be in writing and shall be mailed by first class mail,
postage prepaid, or otherwise delivered by hand or by messenger including
Federal Express or similar courier service, addressed (a) if to a Holder, at
such Holder's address set forth on Schedule A hereto, or at such other address
as such party shall have furnished to the Company in writing, or (b) if to the
Company at 8122 Datapoint Drive, Suite 1250, San Antonio, Texas 78229, Attn:
Chief Executive Officer, or at such other address as the Company shall have
furnished to the other parties hereto.

            Each such notice or other communication shall for all purposes of
this Agreement be treated as effective upon receipt, if delivered personally or
by courier, or, if sent by mail, at the earlier

                                       15
<PAGE>
of its receipt or 48 hours after same has been deposited in a regularly
maintained receptacle for deposit of the United States mail, addressed and
mailed as aforesaid.

            3.5 Delays or Omissions. Except as expressly provided herein, no
delay or omission to exercise any right, power or remedy accruing to any party
to this Agreement shall impair any such right, power or remedy of such party nor
shall it be construed to be a waiver of any such breach or default, or an
acquiescence therein, or of or in any similar breach or default thereafter
occurring; nor shall any waiver or any single breach or default be deemed a
waiver of any other breach or default theretofore or thereafter occurring. Any
waiver, permit, consent or approval of any kind or character on the part of any
party of any breach or default under this Agreement, or any waiver on the part
of any party of any provisions or conditions of this Agreement, must be in
writing and shall be effective only to the extent specifically set forth in such
writing. All remedies, either under this Agreement or by law or otherwise
afforded to any party to this Agreement, shall be cumulative and not
alternative.

            3.6 Severability. In the event that any provision of this Agreement
becomes or is declared by a court of competent jurisdiction to be illegal,
unenforceable or void, this Agreement shall continue in full force and effect
without said provision.

            3.7 Titles and Subtitles. The titles and subtitles used in this
Agreement are used for convenience only and are not considered in construing or
interpreting this Agreement.

            IN WITNESS WHEREOF, this Registration Rights Agreement has been
executed by the undersigned effective upon the date first set forth above.

                                    "COMPANY"

                                    BIONUMERIK PHARMACEUTICALS, INC.

                                    By: /s/ FREDERICK H. HAUSHEER
                                        -------------------------------------
                                    Title: Chairman & Chief Executive Officer

                                       16
<PAGE>
                                   SCHEDULE A

                                     HOLDERS

                                       17<PAGE>

                                                                    EXHIBIT 10.1

                                                                    CONFIDENTIAL

CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTION.

                          STRATEGIC ALLIANCE AGREEMENT

                                     BETWEEN

                        BIONUMERIK PHARMACEUTICALS, INC.

                                       AND

                         ASTA MEDICA AKTIENGESELLSCHAFT

                              18TH OF JANUARY, 2001
<PAGE>
                                TABLE OF CONTENTS
<TABLE>
<S>                                                                                                        <C>
RECITALS ................................................................................................      1

1. DEFINITIONS ..........................................................................................      1
   1.1      Affiliate(s).................................................................................      2
   1.2      Alliance Steering Committee..................................................................      2
   1.3      ASTA Medica Improvements.....................................................................      2
   1.4      ASTA Medica Know-How.........................................................................      2
   1.5      ASTA Medica Patent Rights....................................................................      2
   1.6      BioNumerik Improvements......................................................................      2
   1.7      BioNumerik Know-How..........................................................................      3
   1.8      BioNumerik Patent Rights.....................................................................      3
   1.9      BNP7787......................................................................................      3
   1.10     Budget.......................................................................................      3
   1.11     Competitor...................................................................................      4
   1.12     Confidential Information.....................................................................      4
   1.13     Costs........................................................................................      4
   1.14     Development Plan.............................................................................      4
   1.15     Fiscal Year..................................................................................      4
   1.16     Government Regulatory Approvals..............................................................      4
   1.17     Gross Profits................................................................................      4
   1.18     Gross Sales..................................................................................      4
   1.19     Improvements.................................................................................      5
   1.20     Know-How.....................................................................................      5
   1.21     Parties......................................................................................      5
   1.22     Patents......................................................................................      5
   1.23     Patent Rights................................................................................      5
   1.24     Product(s)...................................................................................      5
   1.25     Product Trademark............................................................................      6
   1.26     Supply Agreement.............................................................................      6
   1.27     Territory....................................................................................      6
   1.28     Trademarks...................................................................................      6
2. GRANT OF RIGHTS ......................................................................................      6
   2.1      Research and Development License.............................................................      6
   2.2      License to Market, Sell and Distribute.......................................................      6
   2.3      Sublicenses..................................................................................      7
   2.4      Canada Right of First Offer..................................................................      7
   2.5      Retention of Rights..........................................................................      7
   2.6      Provision of Know-How........................................................................      8
   2.7      Distribution.................................................................................      8
   3.       MANAGEMENT OF RELATIONSHIP...................................................................      8
   3.1      Steering Committee...........................................................................      8
   3.2      Project Team.................................................................................      9
   3.3      Additional Teams and Assistance..............................................................     10
   3.4      Cooperation..................................................................................     10
   3.5      Voting and Dispute Resolution................................................................     10
   3.6      Costs of Maintenance and Operation...........................................................     10
   4.       DEVELOPMENT PLAN AND COSTS...................................................................     11
   4.1      Development Costs............................................................................     11
   4.2      Government Approvals and Clinical Trials.....................................................     11
</TABLE>

                                        i
<PAGE>
<TABLE>
<S>                                                                                                        <C>
   4.3      Development Plan and Budget..................................................................     12
   4.4      Promotional Materials involving BioNumerik and Labeling......................................     13
5. LICENSE FEES AND ROYALTIES ...........................................................................     13
   5.1      License Fees.................................................................................     13
   5.2      Royalties....................................................................................     13
   5.3      Expiration of Royalty Obligations............................................................     14
   5.4      Inclusion of Sublicense Fees.................................................................     14
   5.5      Sales Forecast and Payment...................................................................     14
   5.6      Forecast Adjustment..........................................................................     15
 6.INFORMATION SHARING ..................................................................................     15
   6.1      Sharing of Information.......................................................................     15
   6.2      BioNumerik Information.......................................................................     16
   6.3      Additional Information Sharing...............................................................     16
7. MANUFACTURING ........................................................................................     17
   7.1      Manufacturing Rights.........................................................................     17
   7.2      Non-Exclusive Manufacturing Option for Territory.............................................     17
   7.3      Pre-Commercial Manufacturing.................................................................     18
   7.4      Commercial Supply Agreement..................................................................     18
   7.5      No Infringing Manufacture or Supply..........................................................     19
8. DILIGENCE ............................................................................................     19
   8.1      General Diligence Efforts....................................................................     19
   8.2      Target Development and Commercialization Plan................................................     19
 9.PATENT MATTERS .......................................................................................     20
   9.1      BioNumerik Patent Maintenance................................................................     20
   9.2      ASTA Medica Patent Maintenance and Assistance................................................     21
   9.3      BioNumerik Patent Representations............................................................     21
   9.4      ASTA Medica Patent Representations...........................................................     21
   9.5      Enforcement of Patents and Proprietary Rights................................................     22
10.TRADEMARKS AND TRADEMARK RIGHTS ......................................................................     23
   10.1     Registration, Maintenance and Ownership......................................................     23
11.IMPROVEMENTS .........................................................................................     24
   11.1     BioNumerik Improvements Included.............................................................     24
   11.2     ASTA Medica Improvement Grantbacks...........................................................     25
   11.3     Joint Improvements...........................................................................     25
   11.4     Sublicenses..................................................................................     25
12.CONFIDENTIALITY ......................................................................................     26
   12.1     Confidential and Proprietary Information.....................................................     26
   12.2     Matters not Included as Confidential Information.............................................     26
   12.3     Survival of Confidentiality..................................................................     27
13.PAYMENTS, RECORDS AND ACCOUNTING .....................................................................     27
   13.1     Means of Payment.............................................................................     27
   13.2     Currency.....................................................................................     27
   13.3     Access to Records............................................................................     28
   13.4     Taxes and Required Withholdings..............................................................     28
14.DURATION AND TERMINATION OF AGREEMENT ................................................................     28
   14.1     Duration.....................................................................................     28
   14.2     Termination..................................................................................     29
   14.3     Effect of Expiration or Termination..........................................................     31
   14.4     Termination for BioNumerik's Breach, Change in Control or Bankruptcy.........................     31
   14.5     Termination for ASTA Medica's Breach, Change in Control or Bankruptcy........................     32
</TABLE>

                                       ii
<PAGE>
<TABLE>
<S>                                                                                                        <C>
   14.6     Termination Due to Cessation of Regulatory Authorization or Lack of Patent Coverage..........     32
   14.7     Sale of Inventory............................................................................     33
   14.8     Country Specific Termination of Rights.......................................................     33
15.BIONUMERIK REPRESENTATIONS & WARRANTIES ..............................................................     33
   15.1     Due Organization and Authority...............................................................     33
   15.2     Safety of Product(s).........................................................................     34
   15.3     Warranties on Quality of the Know-How........................................................     34
   15.4     Governmental Agencies and Product Documentation..............................................     34
   15.5     Circumstances and Acts.......................................................................     34
16.ASTA MEDICA REPRESENTATIONS AND WARRANTIES ...........................................................     35
   16.1     Due Organization and Authority...............................................................     35
   16.2     Right to Accept License; Due Diligence.......................................................     35
   16.3     Governmental Agencies........................................................................     35
   16.4     Circumstances and Acts.......................................................................     35
17.INDEMNIFICATION ......................................................................................     35
   17.1     Indemnification by BioNumerik................................................................     35
   17.2     Indemnification by ASTA Medica...............................................................     36
   17.3     Mechanics....................................................................................     36
   17.4     Insurance Coverage...........................................................................     36
18.RELATION OF THE PARTIES ..............................................................................     37
19.ASSIGNMENTS ..........................................................................................     37
   19.1     Assignment Restrictions......................................................................     37
   19.2     Sale of Business.............................................................................     38
   19.3     [**]
   19.4     Assignment to Affiliates.....................................................................     38
20.MISCELLANEOUS ........................................................................................     39
   20.1     Regulatory Communications....................................................................     39
   20.2     Adverse Effects..............................................................................     39
   20.3     Market Analysis and Marketing Reports........................................................     39
   20.4     Notice/Reports...............................................................................     40
   20.5      Severability................................................................................     40
   20.6     Counterparts.................................................................................     40
   20.7     Warranty Disclaimer..........................................................................     41
   20.8     Force Majeure................................................................................     41
   20.9     Arbitration..................................................................................     41
   20.10    Export Controls..............................................................................     42
   20.11    Construction / Jurisdiction / Official Language..............................................     42
21.USE OF NAMES .........................................................................................     42
22.ENTIRE AGREEMENT .....................................................................................     43
23.CAPTIONS .............................................................................................     43
</TABLE>

                                      iii

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.
<PAGE>
                          STRATEGIC ALLIANCE AGREEMENT

         THIS AGREEMENT ("Agreement") is made and entered into effective as of
the 18th day of January, 2001, between ASTA Medica Aktiengesellschaft, a German
corporation with its office located at An der Pikardie 10, D-01277 Dresden,
Germany (hereinafter referred to as "ASTA Medica") and BioNumerik
Pharmaceuticals, Inc., a Texas corporation, with its office located at 8122
Datapoint Drive, Suite 1250, San Antonio, Texas 78229, U.S.A. (hereinafter
referred to as "BioNumerik").

                                    RECITALS:

         WHEREAS, BioNumerik is the owner of certain inventions, trade secrets,
know-how and rights relating to a certain medicinal toxicity protecting and
mitigating agent and related compounds denoted as "BNP7787", and has been issued
and has applied for certain patent and trademark rights with respect to BNP7787
and has developed BNP7787 for the treatment and mitigation of various clinically
important toxicities.

         WHEREAS, BioNumerik and ASTA Medica wish to further the development of
BNP7787 for the prevention, treatment and mitigation of various medical
treatment-associated toxicities that are associated with drug administration and
other treatments in designated territories of the world.

         NOW, THEREFORE, in consideration of the financial terms set forth
herein and of the other terms, conditions and agreements contained herein, and
for other good and valuable consideration, the receipt and adequacy of which are
hereby acknowledged, BioNumerik and ASTA Medica hereby agree as follows:

         1. DEFINITIONS. When used in this Agreement, each of the following
defined terms shall have the meanings set forth in this Section. There are other
terms defined in this Agreement parenthetically, and such terms shall have the
meanings apparent from the context in which such terms are parenthetically
defined.

                  1.1 "Affiliate(s)" means, with respect to each Party, any
organization, company, firm, or other entity that controls, is controlled by, or
is under common control with said Party. A company shall be deemed to have
control of another if it owns directly or indirectly a majority of the voting
shares of or is

                                       1
<PAGE>
entitled directly or indirectly to appoint a majority of the directors or other
managing body of the other company.

                  1.2 "Alliance Steering Committee" means the Alliance Steering
Committee described in Section 3 hereof.

                  1.3 "ASTA Medica Improvements" means any and all inventions,
developments, discoveries, and improvements useful in the development,
manufacture or sale of the Product(s), including, without limitation, formulae,
compounds, specifications, designs, chemical and physical data, clinical data,
information concerning synthesis, processes, formulations, applications,
toxicity, operations, regulatory affairs and marketing, that are developed by or
for ASTA Medica subsequent to the date of the Confidentiality Agreement between
BioNumerik and ASTA Medica dated as of December 12, 1998 (the "BioNumerik
Confidentiality Agreement") and during the term of this Agreement, subject in
all cases to any restrictions that may exist on the ability of ASTA Medica to
license such inventions, developments, discoveries or improvements to BioNumerik
in accordance with Sections 11 and 14 of this Agreement.

                  1.4 "ASTA Medica Know-How" means all data and information
owned by ASTA Medica and useful in the development, manufacture or sale of the
Product(s), including, without limitation, formulae, specifications, designs,
chemical and physical data, clinical data, information concerning synthesis,
processes, formulations, manufacture of the Active Pharmaceutical Ingredient
(API) for the Product(s), applications, administration to patients, clinical
protocols, toxicity, operations, regulatory affairs and marketing, that have
been developed by or for ASTA Medica on or before the date of the BioNumerik
Confidentiality Agreement, subject in all cases to any restrictions that may
exist on the ability of ASTA Medica to use and license such know-how in
accordance with the terms of this Agreement.

                  1.5 "ASTA Medica Patent Rights" means all patents or patent
applications (excluding the BioNumerik Patent Rights) owned or controlled by
ASTA Medica relating to ASTA Medica Know-How, ASTA Medica Improvements or other
matters that are useful in the development, manufacture or sale of the
Product(s) or that bear some tangible relationship to the Product(s).

                  1.6 "BioNumerik Improvements" means any and all inventions,
developments, discoveries and improvements useful in the development,
manufacture or sale of the Product(s), including, without limitation, formulae,
compounds, specifications, designs, chemical and physical data, clinical data,

                                       2
<PAGE>
information concerning synthesis, processes, formulations, applications,
toxicity, operations, regulatory affairs and marketing, that are developed by or
for BioNumerik subsequent to the date of this Agreement and during the term of
this Agreement, subject in all cases to any restrictions that may exist on the
ability of BioNumerik to license such inventions, developments, discoveries or
improvements to ASTA Medica in accordance with the terms of this Agreement.

                  1.7 "BioNumerik Know-How" means all data and information owned
by BioNumerik and useful in the development, manufacture or sale of the
Product(s), including, without limitation, formulae, specifications, designs,
chemical and physical data, clinical data, information concerning synthesis,
processes, formulations, manufacture of the API for the Product(s),
applications, administration to patients, clinical protocols, toxicity,
operations, regulatory affairs and marketing, that have been developed by or for
BioNumerik on or before the date of this Agreement, subject in all cases to any
restrictions that may exist on the ability of BioNumerik to license such
know-how to ASTA Medica in accordance with the terms of this Agreement.

                  1.8 "BioNumerik Patent Rights" means all patents and patent
applications and utility models and utility model applications (also known as
"gebrauchsmuster"), including any addition, continuation, continuation-in-part,
or division thereof or any substitute application therefore; any patent issued
with respect to such patent application; any reissuance, re-examination or
extension, including Supplementary Protection Certificates, of any such patent,
in each case which patent or patent application bears some tangible relationship
to the Product(s) and in which BioNumerik has an ownership or control during the
term of this Agreement. BioNumerik Patent Rights shall include but not be
limited to those patent applications listed on Attachment A hereto. For purposes
of this Agreement, "gebrauchsmuster" shall mean the protection of technical
inventions as defined in the current German Gebrauchsmuster Law or a legal
institutes comparable to the "Gebrauchsmuster" within the Territory in a state
other than Germany where applicable.

                  1.9 "BNP7787" means the compounds described on Attachment B
hereto.

                  1.10 "Budget" means the annual budget approved from time to
time by the Alliance Steering Committee pursuant to Section 4.

                                       3
<PAGE>
                  1.11 "Competitor" of a Party shall mean a company or
organization engaged in the business of discovering, developing, manufacturing
and/or selling any products or services that compete with any of the Product(s)
or any of the other material products that such Party is then developing,
manufacturing, selling or having sold.

                  1.12 "Confidential Information" means all information that is
of a confidential and proprietary nature, including without limitation, trade
secrets, inventions and unpatented Know-How and Improvements and related
technology, and any and all material information either of the Parties hereto
may acquire concerning the financial, business and marketing goals and plans of
the other, including the terms of this Agreement and (a) what has been disclosed
by BioNumerik to ASTA Medica under the existing BioNumerik Confidentiality
Agreement, and (b) what has been disclosed by ASTA Medica to BioNumerik under
the existing Confidentiality Agreement (the "ASTA Medica Confidentiality
Agreement") dated as of September 28, 2000, between ASTA Medica and BioNumerik.

                  1.13 "Costs" means [**].

                  1.14 "Development Plan" means the plan for the development and
commercialization of the Product(s) approved from time to time by the Alliance
Steering Committee pursuant to Section 4.

                  1.15 "Fiscal Year" means ASTA Medica's fiscal year commencing
on January 1 and ending on December 31 of each year.

                  1.16 "Government Regulatory Approvals" means all government
approvals, health registrations and/or permits required for manufacture, sale,
and distribution of Product(s) in the Territory.

                  1.17 "Gross Profits" means [**].

                  1.18 "Gross Sales" means [**].

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       4
<PAGE>
                  1.19 "Improvements" means the BioNumerik Improvements and the
ASTA Medica Improvements.

                  1.20 "Know-How" means the BioNumerik Know-How and the ASTA
Medica Know-How.

                  1.21 "Parties" means ASTA Medica and BioNumerik, or if used in
the singular, ASTA Medica or BioNumerik.

                  1.22 "Patents" means those patents that embody the Patent
Rights in the Territory.

                  1.23 "Patent Rights" means the BioNumerik Patent Rights and
the ASTA Medica Patent Rights.

                  1.24 "Product(s)" means any pharmaceutical preparation,
composition, product, method of administration or treatment use, or formulation
for administration that contains BNP7787, a related thiol or disulfide,
metabolites or another related cytoprotective agent.

[**]
None of BioNumerik's other agents in discovery or development (including, but
not limited to, karenitecin, MDAM, and preclinical candidates) are included in
this Agreement.
[**]

                  1.25 "Product Trademark" means the main (global) trademark for
the Product(s) in the Territory.

                  1.26 "Supply Agreement" has the meaning set forth in Section 7
hereof.

                  1.27 "Territory" shall mean worldwide, except for the United
States of America (and its possessions and territories), Canada (and its
possessions and territories), and Japan (and its possessions and territories).

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       5
<PAGE>
                  1.28 "Trademarks" means (i) the brand name(s) selected and
owned either by BioNumerik alone or by ASTA Medica to be used for or in
connection with the Product(s) in the Territory (including the Product
Trademark, alternative trademarks to the Product Trademark) and all associated
logos, and (ii) the general reference trade name selected by BioNumerik for
BNP7787 and Product(s).

         2. GRANT OF RIGHTS.

                  2.1 Research and Development License. Subject to the terms of
this Agreement, BioNumerik hereby grants to ASTA Medica and its Affiliates an
exclusive license in the Territory under the BioNumerik Patent Rights,
BioNumerik Know-How and BioNumerik Improvements to conduct and have conducted
research and development (including studies and clinical trials) of the
Product(s) in the Territory for the purpose of obtaining Government Regulatory
Approvals in the Territory.

                  2.2 License to Market, Sell and Distribute. Subject to the
terms of this Agreement, BioNumerik hereby grants to ASTA Medica and its
Affiliates an exclusive license in the Territory under the BioNumerik Patent
Rights, BioNumerik Know-How and BioNumerik Improvements to make, have made, use,
market, distribute, sell, and offer for sale the Product(s) in the Territory.

                  2.3 Sublicenses. ASTA Medica shall have the right to
sublicense the rights granted under Sections 2.1 and 2.2 to third parties in the
Territory subject to the prior written consent of BioNumerik, which will not be
unreasonably withheld. ASTA Medica and BioNumerik agree that BioNumerik shall
have reasonable grounds to object if [**], or (ii) the overall compensation
structure of the sublicense terms are not fair to BioNumerik. ASTA Medica shall
remain fully responsible to BioNumerik for the actions or failure to act of any
of its sublicensees.

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       6
<PAGE>
                  2.4 Canada Right of First Offer. In the event BioNumerik or
its Affiliates do not wish to pursue marketing, distribution and/or sale of the
Product(s) in Canada on their own, BioNumerik shall provide ASTA Medica with
written notice (the "Canada Notice") to such effect. ASTA Medica shall have a
right of first offer to negotiate with BioNumerik to obtain a license with
respect to the Product(s) in the territory of Canada. The first offer right
granted herein will expire 45 days after ASTA Medica's receipt of the Canada
Notice. If no proposal to obtain a license with respect to the Product(s) for
the territory of Canada is made to BioNumerik by ASTA Medica within such 45 day
period, ASTA Medica's right of first offer shall terminate. In the event ASTA
Medica does make a proposal for the territory of Canada within such time period,
then BioNumerik and ASTA Medica will negotiate in good faith during the
remainder of such 45 day notice period and for an additional 90 day period (the
"Negotiation Period") in an effort to enter into a license agreement for such
territory on mutually agreeable terms. If a license has not been executed by the
end of the Negotiation Period, then BioNumerik shall be free to enter into a
third party license and/or alliance with respect to the Product(s) for the
territory of Canada, provided the economic terms of such license and/or alliance
are no more favorable to such third party than the terms last proposed by ASTA
Medica before expiration of the Negotiation Period.

                  2.5 Retention of Rights. BioNumerik shall retain the right for
itself and its Affiliates to use the BioNumerik Patent Rights, BioNumerik
Know-How, and BioNumerik Improvements in the Territory without cost for internal
research and development purposes, for purposes of co-developing the Product(s)
in the Territory with ASTA Medica as approved by the Alliance Steering
Committee, for purposes of manufacturing the Product(s) in the Territory in
accordance with this Agreement, and for purposes that do not relate to the
Product(s). In addition, BioNumerik, its Affiliates, and other parties
previously or hereafter authorized by BioNumerik shall retain the right to
conduct and have conducted research and development (including studies and
clinical trials) of the Product(s) throughout the world for the purpose of (a)
obtaining regulatory approvals outside the Territory, and (b) obtaining
additional data and information regarding the Product(s). BioNumerik will not
conduct any such research and development in the Territory without the prior
consent of ASTAMedica, which consent will not be unreasonably withheld.
BioNumerik may continue to conduct its existing preclinical studies and Phase I
clinical trials relating to the Product(s) in the Territory. In addition,
nothing contained herein is intended to limit the right of ASTA Medica or
BioNumerik to discover, develop, market, or sell other therapeutic products or
technologies throughout the world.

                  2.6 Provision of Know-How. As soon as practicable after the
date of this Agreement and on a regular basis thereafter during the term of this
Agreement, BioNumerik will, subject to the

                                       7
<PAGE>
confidentiality and other terms contained herein, make additional BioNumerik
Know-How available to ASTA Medica.

                  2.7 Distribution. Except as expressly provided in this
Agreement or by a separate written mutual agreement between the Parties,
BioNumerik shall not directly or indirectly distribute or sell Product(s) in the
Territory. Except as expressly provided in this Agreement or by a separate
mutual written agreement between the Parties, ASTA Medica shall not directly or
indirectly manufacture Product(s) to be sold in the Territory or manufacture,
market, distribute or sell Product(s) outside the Territory, unless otherwise
permitted pursuant to a separate agreement that may be entered into by the
Parties pursuant to Section 7.2..

         3. MANAGEMENT OF RELATIONSHIP.

                  3.1 Steering Committee.

                     (a) Formation. Promptly upon execution of this Agreement,
BioNumerik and ASTA Medica will establish an Alliance Steering Committee. The
Alliance Steering Committee shall manage all aspects of the business and
strategic relationship between the Parties with respect to the development of
the Product(s) in the Territory in accordance with the terms of this Agreement.

                     (b) Responsibilities. The Alliance Steering Committee will
have responsibility for overseeing the implementation, performance and
coordination of all development, regulatory, manufacturing, distribution,
selling and marketing activities relating to the Product(s) in the Territory and
for effective communication regarding operations and strategies that are
important for the development of the Product(s). As part of its
responsibilities, the Alliance Steering Committee shall be responsible for
approving the Product Development Plan and Budget. The Alliance Steering
Committee will also monitor the performance of research and development work
relating to the Product(s) in the Territory. The Parties shall report to the
Alliance Steering Committee on all significant clinical and regulatory issues
relating to the Product(s), and the Alliance Steering Committee shall make
recommendations and provide strategic guidance with respect to such issues.

                     (c) Composition. The Alliance Steering Committee shall be
comprised of at least 2 and up to 4 members total as may be agreed to from time
to time by ASTA Medica and BioNumerik. The initial Alliance Steering Committee
will be comprised of [**] who will serve as Co-Chairs of the

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       8
<PAGE>
Alliance Steering Committee. The selection of Alliance Steering Committee
members shall be made by ASTA-Medica and BioNumerik Pharmaceuticals, Inc. as
needed from time to time. The Alliance Steering Committee members shall be
qualified representatives of each company with expertise in oncology drug
development and commercialization operations. The Alliance Steering Committee
will be comprised of an equal number of members from ASTA Medica and BioNumerik,
provided however, that each Party must have on the Alliance Steering Committee
employees holding the following positions: Head of Research and Development and
Head of Sales and Marketing. On behalf of BioNumerik, Dr. Hausheer will
communicate strategies, developments and operations relating to the Product(s)
to the Alliance Steering Committee.

                     (d) Meetings. The Alliance Steering Committee will meet at
least quarterly (in Europe, U.S., or by telephone, video conference or internet
- by mutual consent) each calendar year prior to commercialization of the
Product(s) in the Territory. In addition, either Party may request additional
meetings as reasonably required. The Co-Chairs of the Alliance Steering
Committee will be responsible for providing an agenda for each meeting of the
committee at least 10 days in advance of such meeting and shall prepare written
minutes of all committee meetings in reasonable detail. The Co-Chairs shall
distribute a draft or final written version of such minutes to all members of
the Alliance Steering Committee within 20 days after the relevant meeting.

                  3.2 Project Team. The Alliance Steering Committee will
establish a Project Team that will be responsible for managing the day-to-day
development and registration aspects of the Development Plan. The Project Team
will be comprised of the various employees of each Party that are required for
the successful development and registration of the Product(s) in the Territory.
The Project Team will meet regularly, based on a written schedule and other
mutually agreeable considerations as needed to insure effective communication,
coordination and all related operations for development and marketing of the
Product(s) in the Territory.

                  3.3 Additional Teams and Assistance. The Alliance Steering
Committee may establish such other teams or working groups, as it deems
necessary or desirable in connection with the development and commercialization
of the Product(s).

                                       9
<PAGE>
                  3.4 Cooperation. Each Party will utilize its reasonable best
efforts to act reasonably and in good faith to avoid deadlocks at either the
Alliance Steering Committee or Project Team level and to ensure the successful
operations of both the Alliance Steering Committee and the Project Team. To this
end, each Party will make available to both the Alliance Steering Committee and
the Project Team that Party's knowledge and expertise with regard to the
Product(s) and to the development and registration of products of this nature.

                  3.5 Voting and Dispute Resolution. Each of ASTA Medica and
BioNumerik shall have one vote on the Alliance Steering Committee and on the
Project Team. A unanimous vote by both Parties shall be required for a decision
by the Alliance Steering Committee or the Project Team. A quorum of the Alliance
Steering Committee or the Project Team shall exist only if at least one
representative from each Party with authority to cast the vote of the Party on
the matter before the Alliance Steering Committee or the Project Team, as the
case may be, is present. If the Project Team is unable to reach a decision on
any matter, the Project Team shall refer such matter to the Alliance Steering
Committee. If the Alliance Steering Committee is unable to reach a mutual
agreement on any matter, including any matter referred to the Alliance Steering
Committee by the Project Team, the Alliance Steering Committee shall promptly
conduct good faith discussions in an effort to resolve such matter in a
reasonable and mutually satisfactory manner. If the matter is not resolved by
the Alliance Steering Committee representatives of BioNumerik and ASTA Medica
within 60 days after the commencement of such discussions, either Party may
request, in writing, that the matter be resolved by binding arbitration in
accordance with the provisions of Article 20.9 of the Agreement.

                  3.6 Costs of Maintenance and Operation. Each of ASTA Medica
and BioNumerik will bear its own costs and expenses relating to the maintenance
and operation of the Alliance Steering Committee and the Project Team. The
members of the Alliance Steering Committee and the Project Team will each serve
without any additional compensation.

                                       10
<PAGE>
      4.    DEVELOPMENT PLAN AND COSTS.

            4.1   Development Costs. ASTA Medica shall pay all research and
development expenses in order to develop and commercialize the Product(s) in the
Territory. Such costs will include, without limitation, all costs in order to
carry out the Development Plan, including all costs of any non-clinical or
clinical tests or studies required by any applicable regulatory agency in the
Territory, including any associated manufacturing costs. [**]. BioNumerik is
free to have the calculation of such costs audited in the same manner as
provided in the last sentence of Section 5.6. If BioNumerik determines to
conduct a clinical study for the Product(s) in the Territory on its own, after
obtaining ASTA Medica's consent, BioNumerik shall pay the costs of such study,
unless otherwise agreed by the Parties. If ASTA Medica determines to conduct a
clinical study for the Product(s) outside of the Territory on its own, after
obtaining BioNumerik's consent, ASTA Medica shall pay the costs of such study,
unless otherwise agreed by the Parties.

            4.2   Government Approvals and Clinical Trials.

                  4.2.1.   ASTA Medica agrees at its sole expense to (a) conduct
or cause to be conducted all clinical trials and other studies of any nature of
the Product(s) necessary or desirable for obtaining Government Regulatory
Approvals and (b) prepare and submit all documents necessary or desirable for
obtaining Government Regulatory Approvals. The Alliance Steering Committee will
mutually determine the priority of each country in the Territory for
development, registration and marketing of the Product(s) within a reasonable
period of time following the date of this Agreement. The Alliance Steering
Committee will update the priority list on a semi-annual basis. In connection
therewith, ASTA Medica shall, at its own expense and in accordance with the
priorities determined by the Alliance Steering Committee, apply for all health
registrations and Government Regulatory Approvals required to execute and to
perform this Agreement. To the extent permitted by laws in the Territory and if
requested by ASTA Medica, BioNumerik agrees to assist and support the process of
obtaining the Government Regulatory Approvals by providing input and assistance
from Dr. Frederick H. Hausheer regarding the design and conduct of non-clinical
studies, clinical trials, preparation of regulatory submissions and review,
analysis and presentation of laboratory data. During the term of this Agreement,
ASTA Medica shall be the marketing, development and

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       11
<PAGE>
distribution authorization holder of the Product(s) in the Territory unless
otherwise agreed to by the Alliance Steering Committee. ASTA Medica shall keep
BioNumerik regularly and fully informed of the status of the Government
Regulatory Approvals process on a current basis and furnish BioNumerik upon
BioNumerik's reasonable request with copies of all of the documents, data and
other information supplied to or received from applicable government authorities
in connection with the applications for the Government Regulatory Approvals.
Upon receipt of the Government Regulatory Approvals, ASTA Medica shall promptly
furnish BioNumerik copies or other satisfactory evidence thereof. In addition,
ASTA Medica may conduct research and development (including studies and clinical
trials) of the Product(s) outside the Territory for the purpose of supporting
the development and commercialization of the Product(s) in the Territory.
BioNumerik will have the right to review and consent to any such studies and
clinical trials outside the Territory in advance of their commencement, which
consent will not be unreasonably withheld.

                  4.2.2    ASTA Medica shall have ownership (including
reservation of the right to use in the Territory in accordance with this
Agreement) of all data and results obtained by ASTA Medica from the non-clinical
studies, clinical trials and related testing conducted pursuant to Section 4.1
and 4.2.1 (the "ASTA Medica Data and Results"). Each of ASTA Medica and
BioNumerik shall have the right to use the ASTA Medica Data and Results as
described in this Agreement, unless otherwise agreed by the Parties hereto. ASTA
Medica shall also have the right to use data and results obtained by BioNumerik
from the non-clinical studies, clinical trials and related testing conducted for
the Product(s) outside the Territory, provided that such use by ASTA Medica
shall be for the purpose of supporting the development and commercialization of
the Product(s) in the Territory and shall be subject to any existing limitations
on the ability of BioNumerik to provide such data and results to ASTA Medica.

            4.3   Development Plan and Budget. The initial Development Plan and
initial Budget agreed to by the Parties will be developed by the Parties with
final review and approval by the Alliance Steering Committee. The Development
Plan and Budget will be updated by the Alliance Steering Committee on at least a
quarterly basis. Prior to the start of each calendar year, the Alliance Steering
Committee shall meet to review and approve a Development Plan and Budget for the
following calendar year. No material deviations (e.g., major changes in clinical
study design, patient populations, clinical trial endpoints, or the analysis of
such endpoints) from the Development Plan or Budget will occur without prior
approval by the Alliance Steering Committee. The Development Plan will include
the following elements: (a) a clinical trial program for the Product(s) in the
Territory, (b) a Product Registration Plan, (c) a Publication Plan, and (d) a
Distribution, Selling and Marketing Plan for the Product(s). No company
sponsored clinical trial shall be commenced for the Product(s) in the Territory
without the approval of the Alliance Steering Committee. The Budget detail will
contain specific estimates of allocation of administrative and finance costs,
country or

                                       12
<PAGE>
region-specific allocation of "sales force time and effort" (as defined in
Section 5.6), and country specific-profit and loss estimates.

            4.4   Promotional Materials involving BioNumerik and Labeling. To
the extent permissible by law, the Product(s) distributed in the Territory shall
be represented in all labeling and other documentation as jointly developed by
ASTA Medica and BioNumerik. ASTA Medica shall assure inclusion, consistent with
the laws of each country in the Territory, of BioNumerik's name, logo and other
identification in any promotional materials, which inclusion shall be overseen
at the Alliance Steering Committee level. ASTA Medica agrees that promotional
materials for the Product(s) in the Territory shall contain the statement: "
Under license from BioNumerik Pharmaceuticals, Inc." and shall also display the
BioNumerik trademark wherever permitted by law. Product(s) marketed and sold by
ASTA Medica hereunder shall also be marked with appropriate patent numbers or
indicia at BioNumerik's request, subject to ASTA Medica's consent, not to be
unreasonably withheld.

      5.    LICENSE FEES AND ROYALTIES.

            5.1   License Fees.

                  As partial consideration of the rights hereby granted, ASTA
Medica shall pay to BioNumerik a fixed fee of [**] immediately upon the
execution of this Agreement, which fee shall be non-refundable except as
provided in Section 14.5.

            5.2   Royalties. ASTA Medica shall pay BioNumerik a sliding scale
percentage of [**] per Fiscal Year based on the cumulative [**] within the
Territory during the term of this Agreement. All payments to BioNumerik by ASTA
Medica shall be in U.S. dollars.

            Accordingly, ASTA Medica shall pay BioNumerik the following amounts:

                  [**]

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       13
<PAGE>
            5.3   Expiration of Royalty Obligations. The royalty obligations set
forth in Section 5.2 above shall expire on a country-by-country basis in those
countries in which a BioNumerik Patent Right covers the use or sale of
Product(s), effective as of the date upon which the use or sale of Product(s) in
such country would no longer infringe a valid claim of a BioNumerik Patent Right
in the absence of the rights granted hereunder, provided however that (a) all
royalty obligations shall continue on a country-by-country basis until the last
patent expiry of [**] and (b) all royalty obligations shall continue during the
time that any patent application included in the Patent Rights is being
prosecuted. If a new patent is issued in a particular country with respect to
the Product(s) where the royalty obligations have or would have otherwise
expired in such country, the royalty obligations contained in Section 5.2 shall
be renegotiated in accordance with their terms with respect to such country,
provided that (a) the Parties shall assess the new patent together using [**],
and (b) the lower limit of the royalty to BioNumerik with respect to such new
patent in such country will be [**] Royalties on Product(s) shall also continue
to be paid by ASTA Medica pending final resolution of any litigation or dispute
involving ASTA Medica, BioNumerik, the Product(s) or the Patent.

            5.4   Inclusion of Sublicense Fees. All payments or fees of any kind
received by ASTA Medica or its Affiliates from any sublicensee of the Product(s)
shall be included in [**] (including, without limitation, situations where such
payments and fees are made prior to product launch), and BioNumerik shall be
paid a royalty on all such payments and fees in accordance with Section 5.2

            5.5   Sales Forecast and Payment. Within 45 days of the beginning of
each Fiscal Year, the Alliance Steering Committee will agree on the forecast of
sales for such Fiscal Year. The forecast will include a country specific
estimate of sales in the Territory. Based on this forecast, BioNumerik will
receive quarterly installments of the royalty amount expected to be due to
BioNumerik according to the scale described in Section 5.2 at the end of each
calendar quarter from ASTA Medica.

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       14
<PAGE>
            5.6   Forecast Adjustment. Within 45 days after the end of each
Fiscal Year the payments according to the forecasts will be compared with the
actual [**]. If the aggregate estimated payments made by ASTA Medica to
BioNumerik for such year exceed the actual royalty owing for such year,
BioNumerik shall refund the difference within 45 days of such determination. If
the aggregate estimated payments made by ASTA Medica to BioNumerik for such year
are less than the actual royalty owing for such year, ASTA Medica shall pay
BioNumerik the difference within 45 days of such determination. ASTA Medica's
accountant, KPMG, will review all data and calculations of royalty amounts and
payments. This will be done no later than the end of February of the following
Fiscal Year. In addition, the records maintained by ASTA Medica for calculating
[**]. BioNumerik is free to have such data and calculations fully audited at its
own cost by another accounting firm selected by BioNumerik and ASTA Medica will
disclose all such data and calculations to BioNumerik's auditors on a
confidential basis.

      6.    INFORMATION SHARING.

            6.1   Sharing of Information. ASTA Medica will keep BioNumerik
regularly and fully informed of the non-clinical and clinical development
progress, including discussions and correspondence with regulatory authorities
in the Territory for the Product(s), and ASTA Medica shall provide BioNumerik
with copies of all data and developments that arise from research and
development carried out by or on behalf of ASTA Medica on the Product(s)
pursuant to this Agreement, including all Government Regulatory Approvals for
Product(s) in the Territory. Without any further obligation to ASTA Medica,
BioNumerik (and its designated Affiliates, assignees and sublicensees) are
hereby granted the right to use the ASTA Medica Data and Results, for the
purpose of supporting non-clinical studies, clinical trials and product
regulatory approval and development in areas outside of the Territory, but
excluding Japan.

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       15
<PAGE>
            6.2   BioNumerik Information. BioNumerik shall provide ASTA Medica
with copies of all information generated or controlled by it in the course of
satisfying regulatory requirements in the United States, Japan and/or other
areas outside the Territory with respect to the Product(s) that may be useful or
necessary in obtaining Government Regulatory Approvals in the Territory, such as
IND applications, annual reports, protocol amendments, IND amendments,
promotion, marketing, sales, manufacturing and related documents and information
(collectively, the "BioNumerik Data and Results"). Without any further
obligation to BioNumerik, ASTA Medica (and its designated Affiliates, assignees
and sublicensees) are hereby granted the right to use the BioNumerik Data and
Results, for the purpose of supporting non-clinical studies, clinical trials and
regulatory approval and development of Product(s) in the Territory. For purposes
hereof, the term "Data and Results" shall mean the ASTA Medica Data and Results
and the BioNumerik Data and Results.

            6.3   Additional Information Sharing. In recognition of the
significant importance and benefit of sharing with ASTA Medica all data and
information generated with respect to the Product(s) outside the Territory,
BioNumerik agrees to use its reasonable best efforts to provide ASTA Medica with
the opportunity to enter into a Confidentiality Agreement with Grelan
Pharmaceutical Co., Ltd., BioNumerik's partner for the development of the
Product in Japan ("KI Pharma"), for the purpose of direct communication and
exchange of know-how and other confidential information regarding the
Product(s). BioNumerik shall encourage KI Pharma to enter into such an agreement
with ASTA Medica. ASTA Medica agrees that if KI Pharma agrees to share with ASTA
Medica all data and information generated by KI Pharma with respect to the
Product(s) for the purpose of supporting the development of the Product(s) in
the Territory, then ASTA Medica will, on similar terms, agree to share with KI
Pharma all data and information generated by ASTA Medica with respect to the
Product(s) for the purpose of supporting the development of the Product(s) in
Japan and its possessions and territories. ASTA Medica will promptly provide
BioNumerik with a copy of all communications, data and information shared
between KI Pharma and ASTA Medica that are important to the development,
marketing and manufacturing of the Product(s). BioNumerik will endeavor to
organize and facilitate interactions and communications between ASTA Medica and
KI Pharma regarding the Product(s). Dr. Hausheer will oversee these efforts and
the Parties will endeavor to have a meeting with all such companies at least
once each year. In addition, BioNumerik agrees to use its reasonable best
efforts to provide that any

                                       16
<PAGE>
agreement hereafter signed with respect to a license for commercial distribution
of the Product(s) in areas outside the Territory will provide that the licensee
under such license will share with ASTA Medica all data and information
generated by such licensee with respect to the Product(s) for the purpose of
supporting the development of Product(s) in the Territory. In the event a
prospective licensee for the commercial distribution of the Product(s) in areas
outside the Territory will not agree to the sharing of all data and information
as provided above, BioNumerik will consult with ASTA Medica prior to signing any
license agreement with such party and BioNumerik will use its reasonable best
efforts to facilitate and provide an opportunity for discussion between ASTA
Medica, BioNumerik and such prospective licensee with respect to a mutually
satisfactory arrangement for the sharing of data and information. For purposes
of this Agreement, "reasonable best efforts" shall mean those reasonable
commercial efforts that would be used by reasonable business persons in a
similar situation.

      7.    MANUFACTURING.

            7.1   Manufacturing Rights. BioNumerik will retain all manufacturing
rights related to the Product(s) in all parts of the world (including the
Territory), subject to ASTA Medica's non-exclusive option described in Section
7.2.

            7.2   Non-Exclusive Manufacturing Option for Territory. ASTA Medica
is hereby granted the option to bid to manufacture Product(s) for development
and regulatory approval and/or sale in the Territory. From time to time during
the term of this Agreement, ASTA Medica shall, at its option, provide BioNumerik
with a bid containing the price, delivery amount and other material terms under
which it would manufacture Product(s) for the Territory on a non-exclusive
basis. [**]. In the absence of any bid from ASTA Medica to manufacture
Product(s) on substantially competitive terms to BioNumerik's other
manufacturing alternatives, BioNumerik shall be free to utilize such other
alternatives for the manufacture of Product(s) in the Territory.

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       17
<PAGE>
            7.3   Pre-Commercial Manufacturing. BioNumerik will furnish ASTA
Medica with all supplies of Product(s) required by ASTA Medica in order to
conduct the pre-commercialization studies and clinical trials described in
Sections 4.1 and 4.2, which supplies shall be furnished by BioNumerik to ASTA
Medica at a price equal [**].

            7.4   Commercial Supply Agreement. Following execution of this
Agreement, BioNumerik agrees to finalize its processes for the manufacture of
Product(s) as shall be agreed from time to time between itself and ASTA Medica.
Within 24 months prior to the estimated time of the first commercial sale of
Product(s) in the Territory, ASTA Medica and BioNumerik shall enter into a
commercial supply agreement (the "Supply Agreement") to be negotiated in good
faith and to reflect such terms and conditions as shall be reasonably necessary
to govern the manufacture and supply of Product(s) for sale and distribution in
the Territory.

      The Supply Agreement will provide among other things that:

                  (a)   Not later than the end of each calendar year that
commences after execution of the Supply Agreement, ASTA Medica will supply to
BioNumerik an estimate of its requirements of the amount of API or finished
Product(s) in the Territory during the following [**] years, and will update
this estimate at six-month intervals. BioNumerik will notify ASTA Medica within
90 days of receipt of such estimate if it (or its Affiliates) will be unable to
supply the whole or any part of the requirements described in such estimate.
Together with the [**] estimate, ASTA Medica will deliver to BioNumerik firm
orders for its estimated requirements of Product(s) not less than 12 months in
advance of the required date of delivery. Within thirty (30) days of its receipt
of such firm order, BioNumerik shall confirm such order in writing and fulfill
such orders in accordance with ASTA Medica's required date of delivery provided
the quantities specified therein do not exceed those quantities contained in the
previous estimate for the same period and provided that BioNumerik has not
previously advised ASTA Medica that it will be unable to supply all or part of
such quantities.

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       18
<PAGE>
                  (b)   If BioNumerik (or its Affiliates) are unable to meet the
requirements of ASTA Medica and its Affiliates and sublicensees for commercial
quantities of Product(s), then ASTA Medica may fill all of its remaining supply
requirements in excess of the amount provided by BioNumerik (and its Affiliates)
from a third party or parties. In such event, (i) BioNumerik shall grant a
license to ASTA Medica under the BioNumerik Patent Rights, BioNumerik Know-How,
and BioNumerik Improvements to manufacture and have such third party manufacture
Product(s) for the purpose of allowing such remaining supply requirements to be
filled, and (ii) BioNumerik shall also provide such information and reasonable
assistance as may be necessary to allow such third party to manufacture
Product(s) for the purpose of allowing such remaining supply requirements to be
filled.

                  (c)   The cost of the Product(s) under the Supply Agreement
will be based on [**].

                  (d)   ASTA Medica shall be entitled to have BioNumerik's cost
of manufacture and overhead confirmed by an independent firm of accountants to
which BioNumerik has no reasonable objection, but not more than once in any 12
month period, provided, however, that such firm of accountants shall only report
to ASTA Medica the amount of such costs, including overhead, and shall keep
confidential all other information acquired in the course of the examination.
ASTA Medica shall pay the cost of any such audit and the audit shall be
conducted so that it will not disrupt BioNumerik's ongoing business activities.

      The Parties in good faith shall negotiate all other terms of supply and
purchase to be included in the Supply Agreement.

            7.5   No Infringing Manufacture or Supply. In any event, BioNumerik
shall not be required to manufacture or supply Product(s) pursuant to this
Agreement if by so doing it would be liable to suit for infringement or
contributory infringement of the intellectual property rights of a third party.

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       19
<PAGE>
      8.    DILIGENCE.

            8.1   General Diligence Efforts. ASTA Medica agrees to use its best
efforts to commercialize or cause to be commercialized the Product(s) in the
Territory as soon as reasonably plausible, taking into account external
conditions (e.g., economic, demographic, war or change in market) which would
reasonably be expected to adversely affect commercialization of the Product. As
part of such agreement, ASTA Medica shall use best efforts to commercialize,
promote, distribute, sell and establish the Product(s) in accordance with the
specified list of countries in the Territory in accordance with the development
priorities determined by the Alliance Steering Committee as described in section
4.2.1.

            8.2   Target Development and Commercialization Plan. In addition to
the above general diligence requirements, ASTA Medica shall meet the Development
Plan targets determined by the Alliance Steering Committee for the Product(s).
[**]. An extension of the time to meet the development performance requirements
in the previous sentence may be granted upon mutual agreement between ASTA
Medica and BioNumerik.

      9.    PATENT MATTERS.

            9.1   BioNumerik Patent Maintenance. BioNumerik will be responsible
for prosecuting, maintaining and defending the patents covered by the BioNumerik
Patent Rights and BioNumerik will own all BioNumerik Patent Rights. [**].
BioNumerik will, during the term of this Agreement, use reasonable best efforts
to continue to obtain and maintain additional patent protection for the
Product(s). BioNumerik will regularly advise ASTA Medica as to the progress of
its patent applications and registrations in the Territory relating to the
Product(s). BioNumerik will provide ASTA Medica with copies of all official
actions from the patent offices in the Territory. Any reply to those office
actions dealing with the scope of the claims will only be submitted by
BioNumerik or its representative(s) after ASTA Medica's prior input, which input
will be promptly given and will not be unreasonably withheld. ASTA Medica and
BioNumerik

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       20
<PAGE>
will develop a joint strategy as to patent strategy and prosecution in the
Territory with respect to the Product(s). In addition, BioNumerik will advise
ASTA Medica as to the patent strategy and prosecution outside the Territory with
respect to the Product(s). BioNumerik agrees not to file patents on or make use
of any Confidential Information that ASTA Medica has provided or disclosed to
BioNumerik unless it has obtained the prior written consent of ASTA Medica to
such filings or use. BioNumerik agrees to submit confidential pharmacological
and clinical data to patent offices in the Territory when necessary for
prosecution of patents by BioNumerik.

            9.2   ASTA Medica Patent Maintenance and Assistance. ASTA Medica
will be responsible for prosecuting, maintaining, and defending the patents
covered by the ASTA Medica Patent Rights and ASTA Medica will own all ASTA
Medica Patent Rights. [**]. ASTA Medica will regularly advise BioNumerik as to
the progress of its patent applications and registrations in the Territory
relating to the Product(s). ASTA Medica will provide BioNumerik with copies of
all official actions from the patent offices in the Territory. Any reply to
those office actions dealing with the scope of the claims will only be submitted
by ASTA Medica or its representative(s) after BioNumerik's prior input, which
input will be promptly given and will not be unreasonably withheld. ASTA Medica
agrees not to file patents on or make use of any Confidential Information that
BioNumerik has provided or disclosed to ASTA Medica unless it has obtained the
prior written consent of BioNumerik to such filings or use. In addition, ASTA
Medica will advise BioNumerik as to patent strategy and prosecution in the
Territory with respect to the Product(s).

            9.3   BioNumerik Patent Representations. BioNumerik represents and
warrants to ASTA Medica that BioNumerik owns or has applied for all patents,
patent rights, inventions and know-how described in the BioNumerik Patent Rights
and necessary to grant the licenses granted herein. BioNumerik further
represents and warrants that, to the best of its knowledge, the manufacture,
use, sale or development of the Product(s) pursuant to this Agreement will not
infringe or conflict with any third party right or patent and that BioNumerik is
not aware of any pending third party patent application that, if issued, would
be infringed by the manufacture, use, sale or development of the Product(s)
pursuant to this Agreement. BioNumerik has no knowledge that any infringement
referred to above has occurred or of any other litigation or threat of
litigation involving the Product(s), and BioNumerik has not been notified and is
not aware of any actual or potential claims of such infringement or other
litigation involving the Product(s).

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       21
<PAGE>
            9.4   ASTA Medica Patent Representations. ASTA Medica represents and
warrants to BioNumerik that ASTA Medica has no knowledge that any infringement
or conflict with any third party involving the Product(s) has occurred or of any
other litigation or threat of litigation involving the Product(s). ASTA Medica
has not been notified and is not aware of any actual or potential claims of such
infringement or other litigation involving the Product(s). ASTA Medica has had
the opportunity to analyze and perform due diligence on the current BioNumerik
patent portfolio and the patent filing and prosecution status regarding the
Product(s).

            9.5   Enforcement of Patents and Proprietary Rights.

                  (a)   To the extent allowable by law, [**]. BioNumerik shall
promptly advise ASTA Medica of any such Suit, and BioNumerik and ASTA Medica
shall develop a joint strategy with respect to all such Suits and other third
party intellectual property litigation regarding the Product(s) in the Territory
("Other IP Litigation"). ASTA Medica may join as a party to any Suit brought by
BioNumerik, and to the extent required to properly bring such litigation, ASTA
Medica shall join as a party to any Suit brought by BioNumerik in the Territory.
In the event BioNumerik refrains from initiating any Suit, ASTA Medica may bring
such Suit on its own, and if BioNumerik is required as a party to properly bring
or join such Suit, BioNumerik shall, upon ASTA Medica's request, bring such Suit
or join as a party to such Suit. BioNumerik shall have the sole right to decide
to accept or reject any settlement offer regarding the Suits or Other IP
Litigation, provided that the acceptance of any such settlement that negatively
affects ASTA Medica's rights hereunder or the ASTA Medica Patent Rights must be
consented to by ASTA Medica, which consent will not be unreasonably withheld. In
addition, a response regarding a consent requested by BioNumerik will be
provided by ASTA Medica within 5 business days after BioNumerik's request. , If
ASTA Medica is bringing any Suit without BioNumerik, then any settlement
agreement would have to be approved by both Parties to the extent that it may
affect the BioNumerik Patent Rights. The Parties will meet in good faith with
any third party licensee of the Product(s) to discuss the possible contribution
by such third party to the costs of any Suit.

                  (b)   Except as otherwise expressly provided herein, all legal
expenses and costs in such Suits or Other IP Litigation (including attorneys'
fees) (the "Legal Expenses") when jointly prosecuted will be borne 50% by ASTA
Medica and 50% by BioNumerik. in the event only one of the Parties participates
in such litigation, then the Party participating in such litigation shall bear
100% of such Legal Expenses.

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       22
<PAGE>
                  (c)   All recoveries from any Suit (including attorneys' fees)
and from all Other IP Litigation regarding the Product(s) in the Territory
(regardless of which Party actually receives such recovery) shall be applied
first in or toward satisfaction of all out of pocket expenses borne by ASTA
Medica and BioNumerik proportionately in connection with such Suit or Other IP
Litigation. If any surplus remains it shall be divided equally between ASTA
Medica and BioNumerik, provided that in the event that only one of the Parties
is responsible for the prosecution of a Suit or Other IP Litigation, then the
recoveries from such Suit shall be solely awarded or paid to such Party.

                  (d)   Each of ASTA Medica and BioNumerik shall give the other
Party full and complete access to all information such other Party reasonably
requests related to such Suits or Other IP Litigation

      10.   TRADEMARKS AND TRADEMARK RIGHTS.

            10.1  Registration, Maintenance and Ownership.

                  10.1.1   BioNumerik will use reasonable best efforts to obtain
one global trademark to be used for the Product(s), which is defined in this
Agreement as the "Product Trademark". BioNumerik will inform ASTA Medica at
intervals about the efforts of obtaining the Product Trademark. The choice of
Product Trademark will be made by mutual agreement of BioNumerik and ASTA
Medica. In addition to the foregoing, ASTA Medica will check its pool of
protected trademarks and will provide BioNumerik with potential Product
Trademark proposals if available. If ASTA Medica and BioNumerik select a
trademark for the Product(s) that is owned by ASTA Medica, ASTA Medica shall
grant and hereby does grant BioNumerik an exclusive royalty-free perpetual
paid-up license (with the right to sublicense) to use such trademark in all
parts of the world outside the Territory. If the Parties use a trademark for the
Product(s) that is owned by BioNumerik, BioNumerik shall grant and hereby does
grant ASTA Medica an exclusive royalty-free perpetual paid up license (with the
right to sublicense) to use such Product Trademark in all parts of the
Territory. Should no global Product Trademark be available or should a given
trademark be available but not be acceptable in some jurisdiction (e.g. for
linguistic reasons), the Parties will seek and reach agreement on an alternative
trademark for such jurisdiction. The ownership, use and licensing of such
alternative trademark shall be governed by the same provisions as those
contained herein regarding the ownership, use, and licensing of the Product
Trademark

                  10.1.2   BioNumerik agrees to register and maintain the
Product Trademark at the expense of BioNumerik for use in and association with
Product(s) and such other Trademarks in the Territory in respect of the
Product(s) as ASTA Medica and BioNumerik shall approve. ASTA Medica agrees

                                       23
<PAGE>
to assist in such registration, if requested by BioNumerik and to sell the
Product(s) only under such Trademarks as may be agreed to in writing with
BioNumerik.

                  10.1.3   ASTA Medica agrees that, except for Trademarks
selected from the ASTA Medica pool, as expressly provided in Section 10.1.1
above, and for the name and housemark (logo) "ASTA Medica" both in word and
word-and-design form, BioNumerik shall be the exclusive owner of all registered
and unregistered trademarks and/or service marks associated with the Product(s)
(collectively, "BioNumerik Related Trademark Rights"), including, but not
limited to the Trademarks and the "BioNumerik" name and housemark (logo).

                  10.1.4   BioNumerik shall remain free to use and grant rights
to the use of the Trademarks (a) outside of the Territory and (b) inside of the
Territory with respect to the "BioNumerik" name and housemark (logo) in
connection with products, activities and uses other than the sale and
distribution of Product(s).

                  10.1.5   ASTA Medica acknowledges the validity of the
BioNumerik Related Trademark Rights in the Territory. ASTA Medica shall take due
care not to do or cause to be done any action or omission which adversely
affects the validity of the BioNumerik Related Trademark Rights or jeopardizes
the maintenance thereof, either during the term of this Agreement or thereafter.

                  10.1.6   BioNumerik acknowledges the validity of the
trademarks selected from the ASTA Medica pool in and outside the Territory.
BioNumerik shall take due care not to do or cause to be done any action or
omission which adversely affects the validity of these trademarks or jeopardizes
the maintenance thereof, either during the term of this Agreement or thereafter.

                  10.1.7   ASTA Medica agrees that it will maintain the quality
control standards for the Trademarks and BioNumerik Related Trademark Rights set
forth by BioNumerik and agreed by ASTA Medica (ASTA Medica shall not
unreasonably withhold such agreement) and will ensure that any sublicensee using
the Trademarks and BioNumerik Related Trademark Rights in the Territory shall be
subject to similar standards of quality control.

                                       24
<PAGE>
      11.   IMPROVEMENTS.

            11.1  BioNumerik Improvements Included. During the term of this
Agreement, without any further payment, BioNumerik shall by the next Alliance
Steering Committee meeting fully disclose any BioNumerik Improvements to ASTA
Medica that have not previously been disclosed. In accordance with Section 2
hereof, BioNumerik has granted ASTA Medica an exclusive license to use the
BioNumerik Improvements in the Territory. Notwithstanding the foregoing,
BioNumerik shall, subject to the license grants contained in Section 2 hereof
and in accordance with such Section 2, be free to use any such BioNumerik
Improvements for its own purposes and for the benefit of its designated
Affiliates, assignees, sublicensees, and authorized users without any further
obligation to ASTA Medica, provided that any use of the BioNumerik Improvements
in the Territory shall not interfere with the exercise by ASTA Medica of the
rights granted to ASTA Medica pursuant to this Agreement.

            11.2  ASTA Medica Improvement Grantbacks. During the term of the
licenses granted herein, without any further payment, ASTA Medica shall by the
next Alliance Steering Committee meeting fully disclose any ASTA Medica
Improvements to BioNumerik that have not previously been disclosed. ASTA Medica
agrees to use all ASTA Medica Improvements for the purpose of supporting the
development and commercialization of Product(s) in the Territory in accordance
with this Agreement. In addition, ASTA Medica hereby grants BioNumerik a
non-exclusive, perpetual, worldwide except in the Territory and Japan,
royalty-free paid-up license to all ASTA Medica Improvements, and BioNumerik
(and its designated Affiliates and sublicensees) may, subject to the license
grants contained in Section 2 hereof, make, have made, use, sell and license
products and technology incorporating such ASTA Medica Improvements throughout
the world in areas outside the Territory, but excluding Japan. ASTA Medica
retains the right to practice such ASTA Medica Improvements other than in
connection with the Product(s) in the event of termination of the licenses
granted herein.

            11.3  Joint Improvements. Any new intellectual property jointly
conceived or reduced to practice by ASTA Medica and BioNumerik ("Joint
Improvements") shall be jointly owned by ASTA Medica and BioNumerik on an equal
basis, and all costs to file, prosecute, and maintain patent applications,
patents, and/or other applicable intellectual property protection regarding
Joint Improvements shall be shared equally by BioNumerik and ASTA Medica Each of
BioNumerik and ASTA Medica hereby agrees to license its interest in such
intellectual property in the manner provided in Sections 11.1 and 11.2.

                                       25
<PAGE>
            11.4  Sublicenses. Any sublicense by ASTA Medica of BioNumerik
Improvements or Joint Improvements shall require the prior written consent of
BioNumerik in the manner described in Section 2.3. Any sublicense by BioNumerik
of ASTA Medica Improvements or Joint Improvements shall require the prior
written consent of ASTA Medica, which will not be unreasonably withheld. Any
sublicense by either Party of Joint Improvements shall require the prior written
consent of the other Party, which shall not be unreasonably withheld.

      12.   CONFIDENTIALITY.

            12.1  Confidential and Proprietary Information. Each Party hereto
acknowledges that in order for BioNumerik and ASTA Medica to carry out their
respective obligations under this Agreement, it may be necessary for BioNumerik
and ASTA Medica to disclose to each other certain Confidential Information. Each
Party hereto agrees:

                  12.1.1   To ensure that it does not reveal or make available
any Confidential Information of the other to any third party, except as such
disclosure may be expressly authorized by this Agreement or otherwise
specifically approved in writing by the Party against whom such disclosure is
sought and to ensure that it will treat such Confidential Information of the
other Party in the same manner as it treats its own Confidential Information,
such treatment to be at least the degree that a reasonable person would perform
under similar circumstances;

                  12.1.2   To ensure that Affiliates, sublicensees, employees,
agents, associates or other persons to whom such disclosure may be made or who
may otherwise have access to such Confidential Information of the other have
agreed in writing to safeguard and maintain such Confidential Information of the
other;

                  12.1.3   To ensure that Confidential Information of the other
is not used for the receiving Party's benefit except as such benefits are
expressly contemplated herein;

                  12.1.4   To prohibit the Confidential Information of the other
from being duplicated in any manner; except as is reasonably necessary to
perform the tasks and obligations contemplated under this Agreement; and

                                       26
<PAGE>
                  12.1.5   To prohibit the Confidential Information of the other
from being published in any form without the prior express written consent of
the disclosing Party.

            12.2. Matters not included as Confidential Information.
Notwithstanding anything herein to the contrary, the defined term "Confidential
Information" and the obligations of nondisclosure, nonuse and confidentiality
relating thereto shall not include any information or data which:

                  12.2.1   Is or becomes known to the general public through no
action or fault of the receiving Party;

                  12.2.2   Was already known to the receiving Party without any
obligation of confidentiality prior to the date of disclosure hereunder or under
the ASTA Medica Confidentiality Agreement or the BioNumerik Confidentiality
Agreement, as the case may be, as evidenced by the written records of that
Party;

                  12.2.3   Is or becomes known to the receiving Party without
any obligation of confidentiality from a third party having the right to
disclose the same, and not having a confidential relationship with the
disclosing Party with respect thereto; or

                  12.2.4   Is necessary for the receiving Party or its
Affiliates to disclose to a governmental authority or any agency thereof on a
non-confidential basis, in order to pursue Government Regulatory Approvals or
other regulatory approvals as contemplated by this Agreement or for other
purposes related to the intent of this Agreement, provided, however, that the
receiving Party shall notify the disclosing Party before disclosing such
Confidential Information and shall take such actions as may be available to
restrict the extent of such disclosure and to obtain the protection of such
information to the extent possible.

            12.3  Survival of Confidentiality. The obligations of this Section
12 with respect to Confidential Information shall be in effect during the term
of this Agreement and shall continue indefinitely after the termination of this
Agreement.

      13.   PAYMENTS, RECORDS AND ACCOUNTING.

            13.1  Means of Payment. All payments due by the Parties to each
other under this Agreement shall be made by bank wire transfer in immediately
available funds to a bank account designated by the payee. All payments
hereunder shall be made in U.S. dollars.

                                       27
<PAGE>
            13.2  Currency. In the case of sales made, or costs incurred, in
currencies other than United States dollars, such amounts for payment of
royalties or other payments directed to BioNumerik shall be converted into
United States dollars using a monthly average of the officially published
conversion rate of the European Central Bank, Frankfurt, Germany.

            13.3  Access to Records.

                  (a)   Each Party shall keep (and shall cause its Affiliates
and sublicensees to keep) complete and accurate records and accounts regarding
the performance of its obligations under this Agreement. Such accounts and
records shall be kept at the principal place of business of the respective
Parties (or their Affiliates or sublicensees, as applicable).

                  (b)   Within 90 days after the end of each Fiscal Year, ASTA
Medica's accountant, KPMG, shall audit ASTA Medica's records and accounts
regarding the performance of ASTA Medica's obligations under this Agreement.
Following such audit, KPMG shall provide written confirmation to BioNumerik of
ASTA Medica's performance of its payment and related obligations hereunder.
BioNumerik shall be entitled to have BioNumerik's independent auditor perform an
audit of ASTA Medica's books and records on a confidential basis for the purpose
of confirming ASTA Medica's performance of its obligations under this Agreement,
provided that (i) one such audit may be conducted each year; and (ii) one
additional audit may be conducted each year upon a showing by BioNumerik of
reasonable cause for such audit and obtaining the prior written consent of ASTA
Medica, which consent will not be unreasonably withheld. BioNumerik shall pay
the cost of any such audits and each audit will be conducted so that it will not
disrupt ASTA Medica's ongoing business activities. If any such audit determines
a variation or error in the amounts paid or payable to any Party, the Party
owing such additional amount shall make prompt payment thereof to the other
Party within 45 days of such determination.

            13.4  Taxes and Required Withholdings. All taxes or related
governmental charges levied or assessed with respect to payments by ASTA Medica
to BioNumerik shall be borne by BioNumerik. ASTA Medica will support BioNumerik
to apply for tax reimbursements and/or tax exemption certificates from the
competent German or other tax authorities with respect to such payments.

                                       28
<PAGE>
      14.   DURATION AND TERMINATION OF AGREEMENT.

            14.1  Duration. The term of this Agreement shall commence upon the
date hereof and, unless otherwise terminated as set forth herein, the term of
this Agreement shall expire upon the later to occur of [**]. After expiration of
the term of this Agreement pursuant to clause (i) or (ii) of the preceding
sentence, the licenses granted by BioNumerik to ASTA Medica hereunder shall
automatically become non-exclusive, irrevocable, fully-paid licenses to use
and/or sublicense the use of BioNumerik Know-How to manufacture, use and sell
Product(s) in each country in the Territory where such license has previously
been in effect. In the event one or more countries are eliminated from the scope
of the ASTA Medica license pursuant to this Agreement, the license to ASTA
Medica in Section 2 shall not apply to such countries. In the event of
expiration of this Agreement pursuant to this Section 14.1, the obligations and
rights of the Parties under this Agreement shall terminate, except that the
rights and obligations under this Section 14.1 and under Section 11
(Improvements), 12 (Confidentiality), 17 (Indemnification) and Section 20.9
(Arbitration) shall survive and continue. In addition, the rights of the Parties
to use the ASTA Medica Data and Results and the BioNumerik Data and Results
shall continue as provided in Section 6.

            14.2  Termination.

                  14.2.1   The Parties hereto shall be able to terminate this
Agreement in the following events:

                           (a)   If a Party to this Agreement shall materially
breach, materially default or otherwise materially fail to perform under the
terms of this Agreement, the other Party may terminate this Agreement by giving
60 days advance written notice, unless the breach, default, or failure is cured
within such notice period.

                           (b)   If after Government Regulatory Approvals for
the Product(s) have been obtained, the Product(s) cease to have regulatory
authorization for their sale or distribution in all or substantially all of the
Territory, then either Party may terminate this Agreement upon 60 days advance
written notice, provided that a Party may not terminate this Agreement pursuant
to this clause (b) if the cessation of the Product(s) to have such regulatory
authorization was caused in substantial part by the actions or failure to act of
such Party;

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       29
<PAGE>
[**]

                  14.2.2   If either Party shall become bankrupt or insolvent or
any proceeding is commenced to place its business in the hands of a receiver,
assignee or trustee in bankruptcy, or any proceeding is commenced for company
dissolution, or liquidation, whether voluntarily or otherwise, and such
proceedings are not dismissed within ninety (90) days of the commencement of any
such proceeding, then this Agreement shall automatically terminate to the extent
permitted by applicable law.

                  14.2.3   If, on the date that data package exclusivity,
granted by the EMEA upon approval of BNP7787 for marketing in Europe, for
BNP7787 expires in the European Union, no European Patents have been issued or
allowed that are included in the BioNumerik Patent Rights which protect the
marketing exclusivity of the Product, and which designate at least three of the
countries identified below (the "Major Countries"); then ASTA Medica may
terminate this Agreement upon sixty (60) days written notice to BioNumerik. For
purposes hereof, "Major Countries" means Germany, The United Kingdom, Spain,
France and Italy.

            14.3  Effect of Expiration or Termination. Termination is not the
sole remedy under this Agreement and termination of Product(s) rights or this
Agreement for any reason or the expiration of the term of this Agreement shall
not affect obligations or rights of either Party incurred or accrued prior to
such termination or expiration. The termination of Product(s) rights or this
Agreement shall not affect the right of any Party to recover damages from any
breach of this Agreement.

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       30
<PAGE>
            14.4  Termination for BioNumerik's Breach, Change in Control or
Bankruptcy. In the event (i) ASTA Medica validly terminates this Agreement
pursuant to Section 14.2.1(a), Section 14.2.1(c), or Section 19.3 or (ii) this
Agreement terminates due to the bankruptcy, insolvency, receivership,
dissolution, or liquidation of BioNumerik pursuant to Section 14.2.2, then ASTA
Medica at its option upon written notice to BioNumerik at the time of such
termination may determine to either (a) continue to sell Product(s) in the
Territory, in which event all licenses granted to ASTA Medica (including the
right to use the BioNumerik Improvements) under this Agreement shall survive,
subject to ASTA Medica's continued obligation to pay royalties to BioNumerik
hereunder, or (b) cease selling Product(s) in the Territory, in which event all
rights of BioNumerik to use the ASTA Medica Improvements shall terminate and all
licenses granted to ASTA Medica hereunder shall terminate. In addition, if
requested by ASTA Medica in the event ASTA Medica determines to continue to sell
Product(s) in the Territory, (x) BioNumerik shall grant a non-exclusive license
to ASTA Medica under the BioNumerik Patent Rights, BioNumerik Know-How, and
BioNumerik Improvements to manufacture and have third parties manufacture
Product(s) for distribution and sale in the Territory, and (y) BioNumerik shall
also provide such information and reasonable assistance as may be necessary to
allow ASTA Medica and/or such third parties to manufacture Product(s) for
distribution and sale in the Territory.

            14.5  Termination for ASTA Medica's Breach, Change in Control or
Bankruptcy. In the event (i) BioNumerik validly terminates this Agreement
pursuant to Section 14.2.1(a), Section 14.2.1(c) or Section 19.3, or (ii) this
Agreement terminates due to the bankruptcy, insolvency, receivership,
dissolution, or liquidation of ASTA Medica pursuant to Section 14.2.2, then all
licenses granted to ASTA Medica hereunder and all rights to the Product
Trademark granted to ASTA Medica hereunder shall terminate, all rights to the
Product(s) shall automatically revert to BioNumerik, and ASTA Medica shall
cooperate with BioNumerik in all respects to effect the prompt and efficient
transfer to BioNumerik of product development and marketing activities for the
Product(s) in the Territory and all transferable elements of government
approvals, registrations, or other regulatory approvals and applications
relating to the Products(s) in the Territory. In the event of such termination,
ASTA Medica hereby assigns to BioNumerik all right, title and interest to all
regulatory filings, registrations, applications and approvals pertaining to the
Product(s) and the right to use the ASTA Medica Data and Results for the purpose
of developing and commercializing Product(s) in the Territory. In addition,
contingent upon such termination, ASTA Medica hereby grants to BioNumerik a
non-exclusive, royalty-free license under the ASTA Medica Patent Rights, the
ASTA Medica Know-How, and the ASTA Medica Improvements which are necessary or
useful for the manufacture, use or sale of the Product(s) as such product(s)
exist as of the date of such termination. BioNumerik's rights to

                                       31
<PAGE>
practice such ASTA Medica technology shall be limited exclusively to the purpose
of development and commercialization of products that would be Product(s)
hereunder. [**]. In addition, in the event of such a termination by BioNumerik,
ASTA Medica shall assign to BioNumerik (and/or its designees) an exclusive,
royalty-free, perpetual license in the Territory under (a) the ASTA Medica
Improvements, (b) the ASTA Medica Patent Rights, (c) any rights to the Product
Trademark owned by ASTA Medica, and (d) all other information, findings, and
developments, in each case as such improvements, patent rights, trademark,
information, findings or developments may be developed or generated by ASTA
Medica up to the date of such termination. In addition, ASTA Medica agrees to
provide all reasonable support and assistance, including the preparation and
signing of documents and instruments, as may be requested by BioNumerik in order
to further evidence or reflect the rights to be transferred to BioNumerik
pursuant to this Section.

            14.6  Termination Due to Cessation of Regulatory Authorization or
Lack of Patent Coverage. If this Agreement is terminated pursuant to Section
14.2.1 (b) or by ASTA Medica pursuant to Section 14.2.3, the obligations and
rights of the Parties under this Agreement (including all license grants) shall
terminate and all rights to the Product(s) shall revert to BioNumerik, provided
that the rights and obligations under Section 11 (Improvements), 12
(Confidentiality), 17 (Indemnification) and Section 20.9 shall survive and
continue. In addition, both ASTA Medica and BioNumerik shall retain the right to
use the Data and Results as provided in Section 6 and, in the event this
Agreement is terminated pursuant to Section 14.2.1 (b), BioNumerik and its
assignees and sublicensees may also use such Data and Results for the purpose of
seeking further Government Regulatory Approvals in the Territory following such
termination. In the event of termination by ASTA Medica pursuant to Section
14.2.3, ASTA Medica hereby assigns to BioNumerik all right, title and interest
to all regulatory filings, registrations, applications and approvals pertaining
to the Product(s) that are then in effect.

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       32
<PAGE>
            14.7  Sale of Inventory. Upon valid termination of this Agreement by
BioNumerik pursuant to Section 14.2.1(a) , Section 14.2.1(c) or Section 19.3,
ASTA Medica may, to the extent permitted by applicable law, continue for a
period of up to 6 months to sell in the Territory Product(s) which it has in
inventory at the time of termination; provided, however, that any such sales
shall (i) be made at prices and under terms consistent with previous sales of
the Product(s) by ASTA Medica and (ii) be conducted in a manner so as not to be
harmful to BioNumerik or the market for the Product(s). Payments shall be paid
to BioNumerik in respect of all such sales as otherwise provided in this
Agreement. Except to the extent necessary to sell such existing inventory, ASTA
Medica shall immediately and permanently discontinue the use of the Trademarks
and take all steps necessary to confirm BioNumerik's ownership of such
trademarks and the Government Regulatory Approvals. In the event of such a valid
termination by BioNumerik, BioNumerik shall retain the exclusive right to use
the Data and Results.

            14.8  Country Specific Termination of Rights. If ASTA Medica does
not intend to sell Product(s) in a particular country in the Territory or if
ASTA Medica is not making reasonable ongoing efforts to commence selling
Product(s) in a particular country in the Territory, the license grants
contained in Sections 2.1 and 2.2 hereof shall terminate with respect to such
country in the Territory and such rights shall automatically revert to
BioNumerik. BioNumerik shall then be free to pursue the development, marketing,
sale and distribution of Product(s) in such country.

      15.   BIONUMERIK REPRESENTATIONS & WARRANTIES.

            In addition to the patent representations contained in Section 9.3,
BioNumerik represents and warrants to ASTA Medica as follows:

            15.1  Due Organization and Authority. BioNumerik represents and
warrants: (i) that it is a corporation duly organized, validly existing and in
good standing under the laws of the State of Texas and has the corporate power
and authority to execute, deliver and carry out the terms and provisions of this
Agreement; (ii) that the execution, delivery and performance of this Agreement
by BioNumerik shall not require the consent of any third party, and shall not
cause a breach or violation under any fiduciary, contractual, statutory or
judicial obligation or restraint to which BioNumerik is subject or bound; and
(iii) that the person executing this Agreement on behalf of BioNumerik is duly
authorized to do so to bind BioNumerik.

                                       33
<PAGE>
            15.2  Safety of Product(s). BioNumerik represents and warrants that
is has not received any notification of, and has no knowledge that there is now
pending or that there have been any United States or other judicial or
administrative orders to ban the development or use of BNP7787, and BioNumerik
has no knowledge of any significant or material severe adverse reactions or test
results encountered or discovered regarding the use of BNP7787 which would
render BNP7787 unsuitable or unsafe for the purpose contemplated by this
Agreement, which have not been previously disclosed to ASTA Medica.

            15.3  Warranties on Quality of the Know-How. BioNumerik represents
and warrants to ASTA Medica that the BioNumerik Know-How provided by BioNumerik
under this Agreement is the technology currently utilized by BioNumerik in its
own manufacture, formulations and potential commercial uses of BNP7787.

            15.4  Governmental Agencies and Product Documentation. BioNumerik
represents and warrants that it has disclosed and made available to ASTA Medica
all pertinent correspondence received from any governmental agency, including
patent offices, that relates to or impacts on the ability to develop the
Product(s) hereunder in the Territory and will disclose all such further
information to ASTA Medica in the future. BioNumerik further represents and
warrants that, to the best of its knowledge, the documentation provided by
BioNumerik to ASTA Medica in connection with the Product(s) is accurate and
complete in all material respects and that no such documentation is
intentionally inaccurate or incomplete.

            15.5  Circumstances and Acts. BioNumerik represents and warrants
that it does not know of any circumstances and has not performed any acts that
are inconsistent with the terms or purposes of this Agreement or that may
infringe upon any of the rights of ASTA Medica hereunder.

      16.   ASTA MEDICA REPRESENTATIONS AND WARRANTIES.

            In addition to the patent representations contained in Section 9.4,
ASTA Medica represents and warrants to BioNumerik as follows:

            16.1  Due Organization and Authority. ASTA Medica represents and
warrants: (i) that it is a corporation duly organized, validly existing and in
good standing under the laws of Germany and has the full power and authority to
execute, deliver and carry out the terms and provisions of this Agreement; (ii)
that

                                       34
<PAGE>
the execution, delivery and performance of this Agreement by ASTA Medica shall
not require the consent of any third party and shall not cause a breach or
violation under any fiduciary, contractual, statutory or judicial obligation or
restraint to which ASTA Medica is subject or bound; and (iii) that the person
executing this Agreement on behalf of ASTA Medica is duly authorized to do so to
bind ASTA Medica.

            16.2  Right to Accept License; Due Diligence ASTA Medica represents
and warrants that it has the right, without any restrictions, to accept the
licenses set forth herein. ASTA Medica further represents that it has had the
opportunity to perform due diligence with respect to the Product(s) and has
performed such diligence to the satisfaction of ASTA Medica.

            16.3  Governmental Agencies. ASTA Medica represents and warrants
that it has disclosed and made available to BioNumerik all pertinent
correspondence received from any governmental agency that relates to or impacts
on its ability to develop the Product(s) hereunder in the Territory and will
disclose all such further information to BioNumerik in the future.

            16.4  Circumstances and Acts. ASTA Medica represents and warrants
that it does not know of any circumstances and has not performed any acts that
are inconsistent with the terms or purposes of this Agreement or that may
infringe upon any of the rights of BioNumerik hereunder.

      17.   INDEMNIFICATION.

            17.1  Indemnification by BioNumerik. BioNumerik hereby agrees to
indemnify, hold harmless and defend ASTA Medica from and against any and all
expenses, costs of defense (including without limitation attorneys' fees,
witness fees, damages, judgments, fines and amounts paid in settlement), and any
amounts ASTA Medica becomes legally obligated to pay because of any claim or
claims against it to the extent that such claim or claims (i) are due to product
liability claims arising out of Product(s) supplied to ASTA Medica by BioNumerik
other than to the extent such claims arose out of errors made by or directions
of ASTA Medica, (ii) arise out of manufacturing defects of the Product(s)
supplied by BioNumerik to ASTA Medica, (iii) are due to the non-compliance by
BioNumerik with applicable laws and regulations in the Territory, (iv) arise out
of the breach or alleged breach of any representation or warranty by BioNumerik
hereunder, or (v) are due to the negligence or willful misconduct of BioNumerik;
provided that (a) ASTA Medica provides BioNumerik with prompt notice of any such
claim and the exclusive ability to defend (with the reasonable cooperation of
ASTA Medica) and settle any such claim and (b) such indemnification shall

                                       35
<PAGE>
not apply to the extent such claims are covered by ASTA Medica's indemnity set
forth in Section 17.2 below.

            17.2  Indemnification by ASTA Medica. ASTA Medica hereby agrees to
indemnify, hold harmless and defend BioNumerik from and against any and all
expenses, costs of defense (including without limitation attorneys' fees,
witness fees, damages, judgments, fines and amounts paid in settlement) and any
amounts BioNumerik becomes legally obligated to pay because of any claim or
claims against it to the extent that such claim or claims (i) are due to the
non-compliance by ASTA Medica with applicable laws and regulations in the
Territory, (ii) result from ASTA Medica's activities under this Agreement, (iii)
arise out of the breach or alleged breach of any representation or warranty by
ASTA Medica hereunder, (iv) are due to the negligence or willful misconduct of
ASTA Medica, or (v) arise out of the possession, manufacture, use, sale or
administration of the Product(s) by ASTA Medica or ASTA Medica's Affiliates or
sublicensees (including, without limitation, the release, administration, or
shipment of any Product(s) that is adulterated or fails to meet applicable
manufacturing specifications); provided that (a) BioNumerik provides ASTA Medica
with prompt notice of any such claim and the exclusive ability to defend (with
the reasonable cooperation of BioNumerik) or settle any such claim and (b) such
indemnification shall not apply to the extent such claims are covered by
BioNumerik's indemnity set forth in Section 17.1 above.

            17.3  Mechanics. In the event that the Parties cannot agree as to
the application of Section 17.1 and 17.2 above to any particular loss or claim,
the Parties may conduct separate defenses of such claim. Each Party further
reserves the right to claim indemnity from the other in accordance with Section
17.1 and 17.2 above upon resolution of the underlying claim, notwithstanding the
provisions of Sections 17.1 and 17.2 above requiring the indemnified Party to
tender to the indemnifying Party the exclusive ability to defend such claim or
suit.

            17.4  Insurance Coverage. Each Party represents and warrants that it
is covered and will continue to be covered by a comprehensive general liability
insurance program that covers each Party's activities and obligations hereunder.
Each Party shall provide the other Party with written notice at least fifteen
(15) days prior to any cancellation or material change in such insurance
program. Each Party shall maintain such insurance program, or other program with
comparable coverage, beyond the expiration or termination of this Agreement
during (i) the period that any Product(s) is being commercially distributed or
sold other than for the purpose of obtaining regulatory approvals by ASTA Medica
or by a sublicensee, Affiliate or agent of ASTA Medica and (ii) a commercially
reasonable period thereafter.

                                       36
<PAGE>
      18.   RELATION OF THE PARTIES. The relationship between BioNumerik and
ASTA Medica under this Agreement is that of Parties to an arms-length negotiated
contract. Nothing in this Agreement is intended or is to be construed so as to
create between BioNumerik and ASTA Medica, respectively, the relationship of
partners, or joint ventures, or to establish either Party hereto as the employee
or agent of the other Party hereto. Neither Party hereto has an express or
implied right or authority under this Agreement to make any statement or
commitments of any kind or to assume or to create any obligations on behalf of
or in the name of the other Party hereto, or to bind the other Party hereto to
any contract, agreement or undertaking with any third party

      19.   ASSIGNMENTS.

            19.1  Assignment Restrictions. Subject to Sections 19.2 through 19.4
below, neither Party shall have the right to assign or delegate this Agreement,
or any of its rights or obligations under this Agreement without the other's
express written consent, such consent not to be unreasonably withheld, and said
assignment or delegation without such consent shall be null and void for all
purposes.

            19.2  Sale of Business. BioNumerik or ASTA Medica may assign its
entire interest in this Agreement provided that (i) such assignment is part of
the sale of all or substantially all of the assignor's business related to the
Product(s); (ii) notice of any contemplated assignment is given to the other
Party not less than 30 days prior to the effectiveness thereof; (iii) the
assignor delivers to the other Party a copy of the instrument, duly executed by
the parties thereto, effecting such assignment and affirming a complete
assumption by the assignee of the obligations of the assignor hereunder and a
recognition of the rights of the other Party, and (iv) if the assignment is to a
Competitor, the Parties shall also comply with the procedures set forth in
Section 19.3 prior to any assignment.

      [**]

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       37
<PAGE>
            19.4  Assignment to Affiliates. Subject to Section 19.3, this
Agreement and the obligations hereunder shall be assignable, in whole or in
part, by BioNumerik, without consent of ASTA Medica, to one or more Affiliates
who shall affirm to ASTA Medica a complete assumption of the obligations
assigned; provided that BioNumerik shall guarantee the performance by such
Affiliate(s) of such obligations. Subject to Section 19.3, this Agreement and
the obligations hereunder shall be assignable, in whole or in part, by ASTA
Medica, without consent of BioNumerik, to one or more Affiliates who shall
affirm to BioNumerik a complete assumption of the obligations assigned; provided
that ASTA Medica shall guarantee the performance by such Affiliate(s) of such
obligations. The Parties hereby expressly recognize and agree that,
notwithstanding Section 19.3, if the oncology business unit (the "Oncology
Business Unit") of ASTA Medica shall become a separate legal entity, ASTA Medica
shall be permitted to assign this Agreement to the Oncology Business Unit upon
written notice to BioNumerik, provided that the ultimate ownership of the
Oncology Business Unit shall not have changed from the ultimate ownership of
ASTA Medica prior to such assignment, the Oncology Business Unit shall affirm to
BioNumerik a complete assumption of the obligations assigned, and ASTA Medica
shall guarantee the performance by the Oncology Business Unit of such
obligations.

      20.   MISCELLANEOUS.

            20.1  Regulatory Communications. Each Party agrees to notify the
other immediately by telephone (with prompt written follow-up) of any inquiry,
contact or communication received from any governmental regulatory agency or
other official body that materially and adversely relates to or impacts upon the
Product(s) or any component or ingredient thereof, and will promptly furnish the
other Party with copies of all written communications relating thereto sent to
or received from said regulatory agency.

            20.2  Adverse Effects. Each Party shall promptly inform the other in
writing of any material side effects or adverse effects, conditions or reactions
encountered by or reported to them in connection with the Product(s) which could
in any significant way render the Product(s) or any of the components thereof
unsafe or unfit. The Parties shall follow a written mutually agreed upon
procedure for communication of Adverse Events relating to the Product(s). These
procedures will be agreed to by the Parties prior to the initiation of clinical
trials in the Territory.

                                       38
<PAGE>
            20.3  Market Analysis and Marketing Reports. ASTA Medica shall
provide such analyses and reports as BioNumerik may reasonably request
describing the market for and performance of the Product(s) in the Territory,
the market position and promotion of the Product(s) in the Territory,
competitive product information including pricing and promotional information,
physician and consumer acceptance of the Product(s), and any technical,
promotional or other information developed or obtained by ASTA Medica which
could affect the Product(s) in the Territory or generally. To assist in the
distribution of Product(s) in the Territory, ASTA Medica shall regularly provide
BioNumerik with information and data that will enable BioNumerik to have a
complete update and better understanding of the general and specific markets
relating to the sale of Product(s) in the Territory under consideration. Such
Market Analysis and Reports should be provided and discussed at each Alliance
Steering Committee meeting. BioNumerik shall provide such analyses and reports
as ASTA Medica may reasonably request describing the market for and performance
of the Product(s) outside the Territory, the market position and promotion of
the Product(s) outside the Territory, competitive product information including
pricing and promotional information, physician and consumer acceptance of the
Product(s), and any technical, promotional or other information developed or
obtained by BioNumerik which could affect the Product(s) in the Territory or
generally. To assist in the distribution of Product(s) in the Territory,
BioNumerik shall regularly provide ASTA Medica with information and data that
will enable ASTA Medica to have a complete update and better understanding of
the general and specific markets relating to the sale of Product(s) outside the
Territory under consideration.

            20.4  Notice/Reports. Any reports, notices or other communications
required or permitted to be given by either Party hereto will be given in
writing by personal delivery, courier service or facsimile, or by registered or
certified air mail, postage prepaid, return receipt requested, addressed to each
respective Party at the address shown below.

                  If to BioNumerik:

                  BioNumerik Pharmaceuticals, Inc.
                  8122 Datapoint Drive, Suite 1250
                  San Antonio, Texas 78229
                  Attn:  Frederick H. Hausheer, M.D.
                  Facsimile No.: (210) 614-0643

                  If to ASTA Medica:

                  ASTA Medica Aktiengesellschaft
                  Weismullerstrasse 45
                  60314 Frankfurt am Main, Germany
                  Attn: Dr. Jose-Maria Gimenez-Arnau
                  Facsimile No. ++49/69/4001-2995

                                       39
<PAGE>
or to such other address as either Party may indicate by proper notice to the
other in the same manner as provided herein; provided, however, that the notices
referred to in or required under Sections 9.5 and 14.2. shall be given by
personal delivery, courier service, facsimile, or registered or certified
airmail mentioned above. All notices are deemed effective on the date of receipt
or, if delivery is not accepted, five (5) days after placement with the
addressee, an overnight courier service or a post office, as applicable.

            20.5  Severability. Should any provision of this Agreement be held
to be invalid, unenforceable, or against public policy, the remaining provisions
hereof shall not be affected thereby. In such event, the Parties hereto shall
negotiate in good faith to modify this Agreement so as to effect the original
intent of the Parties as closely as possible with respect to those provisions,
which were held, to be invalid, unenforceable or against public policy.

            20.6  Counterparts. This Agreement may be executed in several
counterparts, each of which will be an original, but all of which, when taken
together, will constitute one and the same instrument.

            20.7  Warranty Disclaimer. EXCEPT AS EXPRESSLY PROVIDED IN SECTIONS
9 AND 15, BIONUMERIK MAKES NO WARRANTY WITH RESPECT TO ANY TECHNOLOGY, GOODS,
SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND HEREBY DISCLAIMS
WARRANTIES OF MERCHANTABILITY, SAFETY, AND FITNESS FOR A PARTICULAR PURPOSE AND
NONINFRINGEMENT WITH RESPECT TO ANY AND ALL OF THE FOREGOING. THE PARTIES
UNDERSTAND AND AGREE THAT DEVELOPMENT AND COMMERCIALIZATION OF BNP7787 AND/OR
PRODUCT(S) WILL INVOLVE APPROVAL BY REGULATORY AUTHORITIES AND THAT NO PARTY IS
GUARANTEEING THE SAFETY OR EFFICACY OF BNP7787 AND/OR PRODUCT(S) OR THAT ANY
REGULATORY AUTHORITY OR AGENCY SHALL GIVE COMMERCIAL APPROVAL OF BNP7787 AND/OR
PRODUCT(S).

            20.8  Force Majeure.

                  20.8.1.  Except for the payment of money, no failure or
omission by the Parties hereto in the performance of any obligation of this
Agreement shall be deemed a breach of this Agreement nor create any liability,
if the same arises as a result of force majeure, i.e., any cause or causes
beyond the control of the Parties, including, but not limited to the following,
which for the purposes of this Agreement, shall be regarded as beyond the
control of the Party in question: acts of God; acts, omissions, rules,
regulations, or

                                       40
<PAGE>
orders of any governmental authority or any officer, department, agency or
instrumentality thereof; flood; earthquake; acts of the public enemy; war;
rebellion; insurrection; riot; invasion; strikes, or lockouts.

                  20.8.2.  In the event of such cause intervening, such excuse
of performance shall be only to the extent that such non-performance is beyond
the reasonable control of the Party bound by such covenant or obligation; and
the Party so affected shall use its reasonable best efforts to eliminate or cure
or overcome any of such causes and to resume performance of its covenants and
obligations with all possible speed.

            20.9  Arbitration. All disputes, controversies or differences which
may arise between the Parties, out of or in relation to or in connection with
this Agreement, or the breach thereof, shall be finally settled by arbitration,
by the International Chamber of Commerce (ICC) Rules in Genf, Switzerland in the
English Language, by a panel of three (3) arbitrators in accordance with the
then current ICC Rules, provided that the arbitrators will first render a
preliminary decision setting forth their grounds for decision and providing at
least thirty (30) days for each of the Parties to respond. The Parties hereto
expressly waive any right to appeal such decision or to challenge the decision
in any court. For purposes of enforcement, the judgment arising from such
arbitration may be entered in any court of competent jurisdiction in the United
States or Germany. This clause shall not be used to prohibit the right of either
Party to seek injunctive relief in appropriate circumstances.

            20.10 Export Controls. The Parties agree to abide by the United
States laws and regulations governing exports of the Product(s) or any other
technology developed or disclosed as a result of this Agreement. The Parties
acknowledge that any performance under this Agreement is subject to any
restrictions that may be imposed by the United States laws and regulations
governing exports. Each Party agrees to provide the other Party with any
assistance, including written assurances, which may be required by a competent
governmental authority and by applicable laws and regulation as a precondition
for any disclosure of technology by the other Party under the terms of this
Agreement. In addition, the Parties hereto agree to take all actions as may
reasonably be required to assure compliance with all applicable requirements of
the U.S. Foreign Corrupt Practices Act.

            20.11 Construction / Jurisdiction / Official Language. This
Agreement shall be construed in accordance with the laws of Switzerland. Each
Party hereto hereby irrevocably consents and submits to the jurisdiction of the
courts of the State of Texas and of the United States of America and of Germany
for purposes of enforcing any judgment that arises from arbitration pursuant to
Section 20.9. English shall be the official language of this Agreement and any
related agreement provided for hereunder and all

                                       41
<PAGE>
communications between the Parties hereto shall be conducted in that language.
Each Party recognizes that the Parties grant no license, by implication or
otherwise, except for the licenses expressly set forth in this Agreement. ASTA
Medica agrees to promptly provide BioNumerik with written English translations
of all important documents that are not in English and relate to the Product(s)
or this Agreement as may be reasonably requested by BioNumerik.

      21.   USE OF NAMES. The Parties hereto understand that each Party may
disclose certain matters pertaining to this Agreement as required by applicable
securities laws or other applicable laws and regulations, which disclosure may
include the name of the other Party and the subject matter of this Agreement,
and be in the form of public statements, whether oral or written, including, but
not limited to, shareholder reports, communications with stock market analysts,
press releases or other communications with the media. Each Party agrees to
coordinate with the other Party press releases and other public statements
regarding this Agreement and the Parties' relationship with regard to the
Product(s). Press releases and other public disclosure involving potentially
sensitive intellectual property matters, product development or marketing
strategies, clinical trials results or other sensitive information must receive
prior written approval by both Parties, which neither Party will unreasonably
withhold. Coordinated common major press releases will be mutually agreed to by
the Alliance Steering Committee in advance of such press release at the
international level. Local market information and abstracts from the common
press releases are not subject to further approval.

      22.   ENTIRE AGREEMENT. This Agreement comprises the entire understanding
and Agreement of the Parties hereto with respect to the specific subject matter
of this Agreement, and supersedes all prior Agreements or understandings,
written or oral, between the Parties hereto with respect to the specific subject
matter of this Agreement. In addition, those obligations under the BioNumerik
Confidentiality Agreement and the ASTA Medica Confidentiality Agreement shall
continue in full force and effect in accordance with their terms. This Agreement
may not be amended except by a written instrument signed by the Parties hereto.

      23.   CAPTIONS. The captions used in this Agreement are for purposes of
clarification only and are not meant to be construed as part of this Agreement.

                                       42
<PAGE>
      IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of
the day and year first written above.

ASTA Medica Aktiengesellschaft           BioNumerik Pharmaceuticals, Inc.

By:   /s/ BERND W. AUNDRUP               By:  /s/ FREDERICK H. HAUSHEER, M.D.
   -----------------------------------      -----------------------------------
      Bernd W. Aundrup                        Frederick H. Hausheer, M.D.
      Chairman of the Executive Board         Chairman & Chief Executive Officer

Date:   18 January 2001                  Date:  18 January 2001
     ---------------------------------        ---------------------------------

                                       43
<PAGE>
                   ATTACHMENTS TO STRATEGIC ALLIANCE AGREEMENT

ATTACHMENT A

      -     BioNumerik Patent Applications in the Territory

ATTACHMENT B

      -     BNP7787 Compounds

ATTACHMENT C

      -     Description and Definitions of Costs, Gross Profits, Gross Sales

                                       44
<PAGE>
                                  ATTACHMENT A

                                      [**]

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       45
<PAGE>
                                  Attachment B

[**]

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       46
<PAGE>
                                  Attachment C

[**]

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       47

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00067-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00067-of-00352.parquet"}]]